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ABSTRACT 
 
Amphibian alkaloids are attractive targets for synthesis due to their biological activity.  
An important class of amphibian alkaloids is the 2,5-disubstituted pyrrolidine-based family of 
compounds.  There are many synthetic approaches for the preparation of the trans-2,5-
disubstituted pyrrolidines, but methods for the construction of the cis-2,5-pyrrolidines are 
limited.  Therefore, it was desired to develop an enantioselective approach for the preparation of 
cis-2,5-disubsituted pyrrolidines.  (+)-Tropin-2-one derived from cocaine was used as starting 
material to exploit the inherent stereochemistry for construction of the cis-pyrrolidine ring.  This 
permitted the unequivocal assignment of the absolute configuration of the target pyrrolidine.  
The structurally simple pyrrolidine alkaloid, 225H, was selected as a target to develop a general 
synthetic approach.  The enantioselective synthesis of 225H was achieved in nine steps and good 
overall yield. 
 
The search for potent cannabinoid receptor partial agonist ligands as potential marijuana 
addiction therapeutic agents has led to an investigation of the synthesis of diaryl ether hybrid 
analogues of BAY 59-3074.  A series of 2-(3-alkyl-5-hydroxyphenoxy)-6-
(trifluoromethyl)benzonitriles, 3-(2-cyano-3-(trifluoromethyl)phenoxy)phenylalkanoates, and (3-
(benzyloxy)phenoxy)-6-(trifluoromethyl)benzonitriles were synthesized and evaluated in vitro 
for CB1 affinity.  The olivetol diaryl ether analogue was the most potent ligand of the alkyl 
series, but the diaryl ester analogues exhibited modest affinity for CB1 receptors.  The most  
potent compound of the series was the 2-(3-(benzyloxy)phenoxy)-6-
(trifluoromethyl)benzonitrile. 
 x
Keywords:  amphibian alkaloids, enantioselective synthesis, pyrrolidine, cannabinoid receptor, 
marijuana.
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CHAPTER 1 
 
 General Strategies for the Construction of Enatiopure Pyrrolidine based 
Alkaloids.  Total Synthesis of (+)-Pyrrolidine 225H 
 
1.1. Abstract 
 
Amphibian alkaloids are attractive targets for synthesis due to their biological activity.  
An important class of amphibian alkaloids is the 2,5-disubstituted pyrrolidine-based family of 
compounds.  There are many synthetic approaches for the preparation of the trans-2,5-
disubstituted pyrrolidines, but methods for the construction of the cis-2,5-pyrrolidines are 
limited.  Therefore, it was desired to develop an enantioselective approach for the preparation of 
cis-2,5-disubsituted pyrrolidines.  (+)-Tropin-2-one derived from cocaine was used as starting 
material to exploit the inherent stereochemistry for construction of the cis-pyrrolidine ring.  This 
permitted the unequivocal assignment of the absolute configuration of the target pyrrolidine.  
The structurally simple pyrrolidine alkaloid, 225H, was selected as a target to develop a general 
synthetic approach.  The enantioselective synthesis of 225H was achieved in nine steps and good 
overall yield. 
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1.2. Introduction 
 
1.2.1. Amphibians 
 
There are eight genera of the family Dendrobatid:  Dendrobates, Phyllobates, 
Epidobates, Aromobates, Minyobates, Manophryne, Nephelobates, and Colosthetus.  Members 
of the genus Dendrobates are also known as the poison dart or poison arrow frog, which were 
named by John Daly and Bernard Witkop.  The poison dart frog is native to southern central and 
northern South America.1  These amphibians are brightly colored, which is an adaptation for 
these animals.  There are a variety of amphibian species that have glandular secretions on the 
skin, which aid in the control of microorganism growth, drying of the skin, and the 
discouragement of predators.  The poison dart frogs do not have a mechanism to deliver the 
poison, but the tissues of these animals are toxic in which these toxins can vary in molecular 
weight and are complex in their organic nature.  Some of the Dendrobatid frogs secrete an 
extremely toxic poison, Batrachotoxin.  However, the only frogs that produce the super deadly 
batrachotoxin are the frogs of genus Phyllobates, in which the Phyllobates terribilis is the most 
toxic.1  The most common use of this toxin is by the Indians of western Colombia for poisoning 
blowgun darts for use in hunting.1  Poison darts are prepared by accumulating the poison from 
the frog’s skin and dipping the dart tips in the toxin, preserving its destructive power for up to a 
year.
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1.2.2. Pyrrolidine Amphibian Alkaloids 
 
A variety of cyclic alkaloids have been characterized from amphibian skin, mainly from 
neotropical dendrobatid frogs.2  The dendrobatid frog does not produce the alkaloid itself, but the 
frog gathers the alkaloid through its diet.  Ants are a major prey for these frogs, particularly frogs 
of genus Dendrobates.2  However, when alkaloid-dusted fruit flies were fed to dendrobatid frogs 
the pyrrolidines accumulated poorly into the skin.3  This suggest that the mechanism by which 
amphibians accumulate these alkaloids is complex and not well understood.  The pyrrolidines of 
interest are rare and minimal in quantity in the dendrobatid frog skin extracts.  The α,α´-
disubstituted pyrrolidines are well-known venom constituents in myrmicine ants of the genus 
Monomorium.2  The 2,5-disubstituted pyrrolidines of the myrmicine ants serve as repellants for 
other ants and have insecticidal activity.2  The 2,5-disubstituted pyrrolidines of these ant venoms 
and frog skin extracts have become attractive synthetic targets.     
 
Figure 1.1:  Amphibian alkaloid structures that contain cis-pyrrolidine subunit 
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The cis-2,5-disubstituted pyrrolidine ring system is the foundation of several classes of 
amphibian alkaloids and exhibits wide-ranging biological activities (Figure 1.1).  The 2,5-
disubstituted pyrrolidine is also a pertinent alkaloid of non-competitive blockers of the nicotinic 
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acetylcholine receptor in addition to other monocyclic and bicyclic alkaloids (Figure 1.1).  
However, the stereochemistry and absolute configurations have not been determined for many of 
these alkaloids.  As yet, the structure of only one pyrrolidine 197B isolated from a dendrobatid 
frog has been firmly established.4   
 
Figure 1.2:  Structure of (+)- and (-)-197B 
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In addition, 197B is the only pyrrolidine that occurs as a major alkaloid, but was determined to 
be the trans-isomer in ant venom.  Both the cis-225H and trans-225H have been synthesized, in 
racemic form, the trans-225H is more common in ants and led to the development of various 
synthetic routes to obtain this structure, while the cis-225H has received little attention.5   
 
Figure 1.3:  Structure of cis and trans-225H 
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Due to the limited sources and non-practical methods for obtaining the cis-225H, a 
general enantioselective synthetic route was desired for the preparation of natural and non-
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natural pyrrolidine alkaloids in order to obtain structural, stereochemical and biological activity 
data.   
 
1.2.3.  Nicotinic Acetylcholine Receptors (nAChRs) 
 
The nicotinic acetylcholine receptor has become the target in understanding various 
health consequences involved in smoking and its mechanisms of action.6  Nicotinic acetylcholine 
receptors are cholinergic receptors that form ionotropic receptors.  Similar to other types of ion 
channels the opening of the nAChR ion channel is triggered by the binding of acetylcholine.  
Acetylcholine is formed from choline and formed by enzymatic reaction with coenzyme A.  This 
neurotransmitter plays a role in memory and is involved in Alzheimer’s Disease.7  Nicotinic 
receptor ion channels are also opened by nicotine.  These nicotinic receptors are the most studied 
ionotropic receptors and are present throughout the tissues in the body.  Nicotinic receptors are 
made up of five subunits around the central pore.   The acetylcholine binding site is on the 
outside of the α subunit near the N terminus.6 As stated earlier amphibian alkaloids engage as 
noncompetitive blockers of nicotinic acetylcholine receptor ion channels.4,8  These amphibian 
alkaloids block channel conductance and accelerate desensitization or inactivation of the 
nicotinic acetylcholine receptor channel.  
 
1.2.4.  Therapeutic Targets 
 
These pyrrolidines are attractive targets in the development of therapeutics that are aimed 
at disease states and disorders mediated by nicotinic acetylcholine receptor ion channels.6  The 
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therapeutic targets of interest include Parkinson’s disease, Alzheimer’s disease, acute and 
chronic pain, Tourette’s syndrome, anxiety disorders, depression, and smoking cessation.  
Likewise, subtype selective regulation of neurotransmitter release creates the possibility to 
develop selective nAChR agents that would target specific neurotransmitters or systems involved 
in neurological and psychiatric disease.6 
Over the past several years, a variety of research groups have focused on the 
development of selective nicotinic agonists. Nicotinic agonists could be useful in the treatment of 
a variety of neurological disorders including Alzheimer's disease, Parkinson's disease and 
chronic pain. Epibatidine (4) is a nicotinic agonist isolated from the skin of an Ecuadorian frog 
Epipedobates tricolor that displays potent analgesic properties and is 200 more times potent than 
morphine.1,9   
 
Figure 1.4: Nicotinic Agonists 
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SIB-1508 (altinicline) 5 is another nicotinic agonist with potential utility in the treatment of 
Parkinson's disease.9,10  
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1.2.4.1.  Alzheimer’s Disease 
 
Alzheimer’s disease is the sixth-leading cause of death in the United States.11  According 
to the Alzheimer’s Association, there are approximately 5.3 million people living with this 
disease.11  There are a variety of possible causes of Alzheimer’s Disease such as the stress 
stemming from catastrophic life events.  It is the most common form of dementia and is also a 
degenerative and fatal brain disorder without a cure.  Alzheimer’s disease accounts for the 
highest percentage of dementia cases. Dementia describes the loss of any recent memory and/or 
other intellectual abilities.  The symptoms of Alzheimer’s disease includes loss of intellectual 
ability, impaired thinking, trouble defining words and concepts, language disturbances (aphasia), 
motor activity difficulty (apraxia), failure in object recognition despite intact sensory and/or 
motor brain functions (agnosia), and personality alteration and/or trait accentuation prior to 
illness (premorbid traits).7,12-14  
There are four identifiable phases of Alzheimer’s Disease:  onset, loss, disability and 
victim apathetic.7  With the onset of Alzheimer’s Disease, an individual may avoid what is 
unfamiliar and prefer familiar faces and places.  In addition, an individual may experience less 
drive, slower reaction time, and difficulty in learning new things.7  The second phase is the 
experience of more loses of familiarity.  An individual may be unable to execute familiar tasks 
and have difficulty with common concepts.7  During this phase, an individual may start to 
require supervision.  The third phase is disability in which an individual may start getting 
disoriented.  At this point, recognition of familiar people and/or places and the track of time and 
place become unrecognizable.  The final phase is victim apathetic.  During this final phase, an 
individual is now unable to find their way around familiar space and may begin wandering to 
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find what seems to be familiar.7  Nonetheless, the individual may now need aid with daily life as 
memory loss begins to be gradual.  There are warning signs such as problems remembering 
particular things and events and/or a slowed thinking process.  These are linked to major changes 
in the way the mind operates, which is not a normal process in aging and could in fact be 
signaling that the brain cells are failing.   
The brain has over 100 billion nerve cells in which each nerve cell communicates with 
many other nerve cells to form networks to carry out particular functions.  Some of these nerve 
cells have certain functions involved in thought, sight, hearing, learning and memory.   However, 
in Alzheimer’s disease, there are huge numbers of brain cells that die, which are consistent with 
a failing brain.  There are three characteristics of brain changes or a failing brain:  neurofibrillary 
tangles, neuritic plaques, and granulovacula degeneration.7,12-14  The neurofibrillary tangles are 
an accumulation of abnormal fibers (twisted tau fibers) concentrated in the cell’s cytoplasm.  
These tangles occur densely in the hippocampus, which is the “seat of emotions” and the location 
of recent and/or short term memory.7  Neuritic plaques build up between the nerve cells and 
contain beta-amyloid deposits. Even though it is possible to develop these plaques and tangles as 
one ages an Alzheimer’s brain will develop them more severely.7  Granulovacula degeneration 
occurs in the interior of the cell in which the cell fills with vacuoles consisting of fluid and 
granular material.  Increases in granulovacular degeneration decreases mental function.7,12-14 
Two abnormal structures called plaques and tangles are prime suspects in damaging and killing 
nerve cells. 
As stated earlier, there are no effective treatments available for Alzheimer’s Disease.  
The treatments that are available are based on treating certain symptoms of the disease such as  
cognitive, behavioral and psychiatric symptoms.11  The memory, language and other thought 
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processes are cognitive symptoms.  The way an individual may feel or acts are both behavioral 
and psychiatric symptoms.  There are a host of medications for treatment of the cognitive, 
behavioral and psychiatric symptoms involved in Alzheimer’s Disease.  The cognitive symptoms 
can be treated with different chemicals involved in carrying messages between the brain’s nerve 
cells.11-13  For example, cholinesterase inhibitors prevent the breakdown of acetylcholine which 
supports the communication among nerve cells by keeping the acetylcholine levels high.  
Examples of cholinesterase inhibitors that are commonly prescribed are Donepezil, 
Rivastigmine, and Galantamine.  The behavioral and psychiatric symptoms are treated with 
antidepressants (Prozac and Zoloft), antipsychotics (clozapine and Abilify), and anxiolytics 
(Ativan).11-13 
 
1.2.4.2.  Parkinson’s Disease 
 
Both men and women equally are affected by Parkinson’s disease.  According to the 
National Parkinson Foundation, 60,000 new cases are diagnosed a year joining the 1.5 million 
Americans currently living with Parkinson’s disease.15  Parkinson’s Disease is a gradual and 
chronic neurodegenerative disease of the central nervous system that impairs speech, motor skills 
and a host of other functions.  It occurs when neurons in the substantia nigra of the brain die or 
become impaired.16  The cells in the substantia nigra produce dopamine, which aids in 
coordination of muscles and movement.17  However, when a significant amount of the 
dopamine-producing cells are impaired, the symptoms of Parkinson's disease can appear.  The 
movement disorders seen in Parkinson’s disease are due to the loss of dopamine production in 
the brain.  The symptoms and/or key signs are characterized the stiffness of muscles (rigidity), 
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slowness and poverty of movement (bradykinesia), balance difficulty, and involuntary shaking 
movements (tremor).15-19  Other signs of Parkinson’s disease include altered facial expressions, 
posture, irregular handwriting, and shuffled walk.   
In the past, the causation of the onset of Parkinson’s disease was unknown.  However, it 
is believed to be caused by genetic abnormalities, toxins, or head trauma.15-19  There is no 
diagnosis to detect Parkinson’s disease as well as no treatment available to slow or stop the 
progression of Parkinson’s disease.  Nonetheless, there are medications available to ease the 
symptoms.  The symptoms of Parkinson’s disease are caused by a lack of dopamine.17  
Therefore, the medications used attempt to mimic dopamine to aid in the improvement of the 
common symptoms associated with Parkinson’s disease. 
Treatments for Parkinson’s disease are approached by exploring neuroprotective and 
dopamine-releasing properties of the nicotinic acetylcholine receptor.  There are a variety of 
commonly prescribed medications for the treatment of Parkinson’s disease.  Levodopa (L-dopa) 
is modified by brain enzymes to produce dopamine to aid in the reduction of symptoms and 
remains the most effective treatment for many Parkinsonian symptoms.15-19  L-dopa is combined 
with an enzyme inhibitor to prevent the breakdown by blood enzymes.  Other treatments include 
dopamine agonists, which do not have to be modified by brain enzymes, but are likely to cause 
other side effects than L-dopa.15-19  These dopamine agonists include amantadine, anticholinergic 
medications, and selegiline, which alter the movement control center in the brain without 
stimulating the dopamine receptors.  Amandtadine was initially studied as an antiviral 
medication, but was found to reduce symptoms of fatigue, tremor, and bradykinesia better used 
for early symptomatic stages.15-19  Anticholinergic medications reduce tremor or rigidity, but are 
used in elderly patients or those with cognitive problems.15-19  Selegiline inhibits monoamine 
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oxidase B, which breaks down dopamine and may aid in the improvement of Parkinson’s 
Disease, but there is no firm evidence to support this claim to date.15-19 
 
1.2.4.3.  Smoking Cessation 
  
The nicotinic acetylcholine receptor has become the target in understanding various 
health consequences involved in smoking and its mechanisms of action.  Nicotine (3) is an 
addictive drug and accounts for more deaths than cocaine and other hard drugs.  The 
combination of nicotine (3) and other components are carcinogenic and can lead to a host of 
cancers.20 Approximately 10% of US lung cancers are attributable to radon, which is recognized 
as the second leading cause of lung cancer.  Tobacco smoke in combination with radon exposure 
has a synergistic effect.20   
Nicotine (3) stimulates acetylcholine receptors and increases the activity of dopaminergic 
neurons of the mesolimbic system.21  When acetylcholine (Ach) is released by an 
acetylcholinergic terminal button, the receptors open briefly and permit calcium ions to enter.  
The calcium ions stimulate neurotransmitter release.   The enzyme AChE destroys Ach and the 
receptors close again or enter a desensitized state during which they bind with but not react to 
AChE.21  Therefore, while smoking a persons’ nicotine level rises slowly in the brain and stays 
steady for a prolonged period because it isn’t destroyed by AChE.  The nicotinic receptors are 
activated but sustained at low levels and converts many of the nicotinic receptors to a 
densensitized state.21  Conceivably, nicotine (3) has dual effects of activation and 
densensitization. 
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 Cessation of smoking after long term use causes withdrawal symptoms, including 
anxiety, restlessness, insomnia and inability to concentrate.21  These symptoms increase the 
likelihood of relapse but don’t explain why the addiction occurs.  The root of withdrawal 
symptoms is the lack of nicotine (3).  Therefore, nicotine replacement is a form of treatment 
which is considered to alleviate withdrawal symptoms leading to a higher success rate of 
cessation.  Addiction can be considered the repetitive administration of drugs to produce positive 
reinforcement.  Desensitization and tolerance development is a result of repetitive exposure due 
to adaptive changes in the organism.22 
Nicotine (3) is the main active ingredient in tobacco.  It is an alkaloid named from 
Nicotiana tabacum and is a cholinergic agonist that micmics the action of acetylcholine.  
Lobeline (6) is an alkaloid that is found in Indian tobacco that aids in drug addiction and is 
currently in the pilot phase III clinical trials.  Lobeline (6) acts as a mixed agonist-antagonist at 
the nicotinic acetylcholine receptor.   
 
Figure 1.5:  Smoking Cessation Aid 
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1.3.  Previous Synthetic Routes 
 
A survey of the literature revealed that the most successful approach for the synthesis of 
cis-2,5-disubstituted pyrrolidines is to employ amino acids as starting materials.  There are many 
advantages to starting with a natural amino acid due to the versatility of the starting material.  
Compounds of this nature are commercially available, and inexpensive.  An example of a 
synthesis using glutamic acid as a starting material proceeds through a β-enaminoester 
intermediate is shown in Scheme 1.1. 
 
Scheme 1.1: Enamine reduction to obtain cis-pyrrolidine   
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The Moloney group performed enamine reduction and subsequent regioselective and 
diastereoselective alkylations to construct cis-2,5-disubstituted pyrrolidines.5,23  The starting 
material for the synthesis is pyroglutamic acid and the lactam carbonyl is manipulated through 
the Eschenmoser contraction by the condensation of a lactam with an α-bromoester.  The 
enaminone products from the Eschenmoser contraction are highly substrate and reagent 
dependent and for β-enamino (mono) esters cis-stereocontrol can be achieved with catalytic 
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hydrogenation.5,23 Benzoylation of the amine 8 nitrogen gave a separable mixture of cis and 
trans products, but there is the possibility of equilibration during acetylation, which may 
complicate future pyrrolidine synthesis.   Therefore, the compound was of limited synthetic 
utility.   
The Carretero group performed catalytic enantioselective 1,3-dipolar cycloaddition of 
azomethine ylides with vinyl sulfones to construct cis-2,5-pyrrolidines.24  
 
Scheme 1.2:  Catalytic Enantioselection to obtain cis-pyrrolidines 
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The outlined procedure uses metal catalyzed asymmetric 1,3-cycloaddition to form the cis-
pyrrolidine.  The use of the CuI-Taniaphos catalyst system was the most enantioselective.  Other 
catalyst systems included Zn(II), Ag(I), Cu(I), Cu(II) complexes with chiral N,N-, P,P-, P,N-, 
P,S- bidendate ligands.24-23  Vinyl sulfones were employed due to the highly electron deficient 
nature of the carbon-carbon double bond (Figure 1.6).   
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Figure 1.6:  Aryl vinyl sulfones 
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The electronic character at the aryl moieties was evaluated.  The aryl vinyl sulfones (e.g., 14a) 
didn’t give enantioselectivity enhancement, but the thiophenyl vinyl sulfone 14b showed similar 
asymmetric induction and the 2-pyridyl sulfone 14c didn’t give an enhancement of 
enantioselectivity whereas the N,N-dimethylamino 14d gave no reaction.22  The dipole 
components were also evaluated and electron rich arenes, electron poor arenes, and ortho, meta, 
para substitutions were employed.  The reactions produced good yields and were exo-
stereoselective, but the bulkier imines were less enantioselective.  Therefore, this procedure is 
limited to substrates that produce the desired enantioselectivity.   
The initial approach to the synthesis of racemic pyrrolidines was based on the reductive 
amination of 1,4-diketones widely used by Jones et al. as shown in Scheme 1.3.25-26 
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Scheme 1.3:  Reductive amination of 1,4-diketones 
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The 1,4-diketone was prepared from alcohol 15 by buffered pyridinium chlorochromate 
oxidation to give the unstable enone 16.25-26  Enone 16 was manipulated through the Stetter 
reaction when treated with the appropriate aldehyde, triethylamine, and a thiazolium salt catalyst.  
The condensation of enone 16 and the aldehyde gave the 1,4-diketone 17.  Treatment of the 1,4-
diketone 17 with ammonium acetate, NaBH3CN and KOH followed by subsequent reduction 
with sodium borohydride of the pyrroline produced a 1:1 ratio of the cis to trans pyrrolidines 1 
and 18, respectively.25-26  The trans-pyrrolidine 225H has been isolated from both the Solenopsis 
molestra and Solenopsis texanas ants and more recently the cis-isomer has been detected in trace 
amounts in the amphibian skin extracts.  Even though, the physical and spectral properties of the 
pyrrolidine 225H were identical to the authentic sample, the compound still has not been fully 
characterized nor has the absolute configuration been determined.  An enantiopure total synthesis 
would allow correlation of the configuration with the specific optical rotation. 
The Trudell group has synthesized two enantiopure cis-2,5-pyrrolidine building blocks 
prepared from cocaine 19 (Scheme 1.4).  Cocaine degradation to (+)-2-tropinone (20) is a one-
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pot three-step synthesis.  Typically performed on a 35g scale this process yields 10g of the 
optically pure chiral building block, 2-tropinone (20).27  Through the degradation of cocaine, the 
inherent stereochemistry of C1 and C5 is exploited.   
 
Scheme 1.4: Chiral building blocks 
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(+)-2-Tropinone (20) was identified as the initial chiral building block for the preparation of 
enantiopure cis-2,5-pyrrolidine 225H.27  This building block was the target for the complete 
synthetic procedure due to its availability and the ease in preparation.  Confiscated grade (-)-
cocaine•HCl 19 was degraded to (+)-2-tropinone (20) in an overall yield of 80% (Scheme 1.5).   
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Scheme 1.5: Synthesis of (+)-2-tropinone 
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The degradation of cocaine 19 furnished (-)-anhydroecgonine 22.  The carboxylic acid 
was suspended in dichloromethane and treated with diphenylphosphoryl azide and DMAP to 
afford the acyl azide 23.  The acyl azide 23 was then refluxed in 1 N hydrochloric acid to afford 
2-tropinone (20) via a Curtius rearrangement.  In Scheme 1.6, the 2-tropinone (20) was 
demethylated and protected as the Cbz-carbamate 24 by refluxing in a solution of Cbz-Cl and 
toluene.  Protection of the nitrogen is needed to reduce basicity and for protection from oxidation 
during the ozonolysis in the subsequent step.27
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Scheme 1.6:  Synthesis of Cbz protected cis-2,5-disubsituted pyrrolidine 
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The Cbz protected 2-tropinone 24 was converted into the methyl enol ether 25 using trimethyl 
orthoformate catalyzed by p-toluenesulfonic acid.  The double bond of the methyl enol ether 25 
was cleaved by ozone at -78 ºC and subsequent reductive workup with triphenylphosphine 
furnished the enantiopure cis-2,5-disubstituted pyrrolidine 26.27   
 
1.4.  Retrosynthetic Approach and Synthetic Strategy 
 
 The retrosynthetic approach utilizing the (+)-2-tropinone (20) chiral building block for 
the preparation of enantiopure cis-2,5-disubstituted pyrrolidine is outlined in Scheme 1.7.  The 
synthesis was envisaged to start from confiscated grade (-)-cocaine•HCl 19.  The first approach 
to the target amphibian alkaloid 225H will utilize similar chemistry as that employed in the 
synthesis of (-)-monomorine.27b  The synthesis will employ the deprotection of the 2,5- 
disubstituted pyrrolidine 31 to afford the amphibian alkaloid 225H (32). 
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Scheme 1.7:  Retrosynthetic approach via (+)-2-tropinone 
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The aldehyde moiety of 29 will be protected as the acetal to afford 30.  The ester moiety of 29 
will undergo reduction followed by concomitant Wittig olefination and hydrogenation to afford 
the five carbon unit necessary for the C2 side chain 32.  The acetal 30 will be hydrolyzed 
followed by concomitant Wittig olefination and subjected to hydrogenation to afford 31.  
Oxidative cleavage and subsequent reductive workup of the methyl enol ether 28 yields the 
enantiopure cis-2,5-disubstituted pyrrolidine 29.  The ethyl carbamate 26 will be converted into 
the methyl enol ether 28.  Cocaine 19 undergoes degradation followed by N-demethylation and 
protection as the ethyl carbamate to afford ethyl carbamate 2-tropinone 27. 
 The retrosynthetic approach utilizing the R-(-)-anhydroecognine methyl ester 21 chiral 
building block for the preparation of enantiopure cis-2,5-disubstituted pyrrolidine is outlined in 
Scheme 1.8.  
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Scheme 1.8:  Retrosynthetic approach via R-(-)-anhydroecognine methyl ester 
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The synthesis was envisaged to start from confiscated grade (-)-cocaine•HCl 19.  The 
chiral building block, anhydroecgonine derivative 33, will be explored as an intermediate in 
approaching amphibian alkaloid (+)-225H (32) as shown in Scheme 1.8.  The synthesis will 
employ the deprotection of the 2,5-disubstituted pyrrolidine 31 to afford the amphibian alkaloid 
225H (32).  The α-ketoester moiety of 34 will undergo reduction, oxidative cleavage followed by 
Wittig olefination to furnish the n-pentyl side chain in 32.  Concomitant hydrolysis of the acetal 
moiety of 32 followed by Wittig olefination and hydrogenation will furnish the ethyl carbamate 
protected methyl ester 31.  Oxidative cleavage and subsequent reductive workup of 33 followed 
by selective protection of the aldehyde as an acetal furnished the enantiopure cis-2,5-
disubstituted pyrrolidine 34.  The synthesis will employ the preparation of anhydroecgonine 
methyl ester 21 from cocaine 19 followed by N-demethylation and protection as the ethyl 
carbamate to furnish 33. 
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1.5.  Results and Discussion 
 
1.5.1.  Synthesis of Chiral Building Blocks 
 
The synthetic approach for the preparation of (+)-2-tropinone (20) is outlined in Scheme 
1.5.  The degradation of cocaine 19 furnished (-)-anhydroecgonine (22) in 93% yield.  The 
carboxylic acid was suspended in dichloromethane and treated with diphenylphosphoryl azide 
and DMAP to afford the acyl azide 23.  The acyl azide 23 was refluxed in 1 N hydrochloric acid 
to afford 2-tropinone (20) via a Curtius rearrangement in 33% yield.  In Scheme 1.9, the 2-
tropinone (20) was demethylated and protected as the ethyl carbamate 27 by refluxing in a 
solution of ethyl chloroformate and toluene in 57% yield.  The protected 2-tropinone 27 was 
converted into the methyl enol ether 28 using trimethyl orthoformate catalyzed by p-
toluenesulfonic acid with a yield of 89% (Scheme 1.9).   
 
Scheme 1.9:  Synthesis of carbamate protected cis-2,5-pyrrolidine disubstituted pyrrolidine 
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Cleavage of the carbon-carbon double bond of methyl enol ether 28 by ozone at -78 ºC 
and subsequent reductive workup with triphenylphosphine should furnish the enantiopure cis-
2,5-disubstituted pyrrolidine 29.  The methyl enol ether 28 was hydrolyzed due to the presence 
of water and was recovered as the ketone 27.  A more versatile enol ether was desired for the 
convenient tropane intermediate necessary for the synthesis of our desired pyrrolidine, 225H.  In 
addition to the unstable methyl enol ether 28, Scheme 1.9 consisted of six steps to yield the 
disubstituted pyrrolidine 29.  Therefore, a stable enol ether intermediate and a more direct 
approach to the cis-pyrrolidine was desired for the cis-2,5-disubstituted pyrrolidine.  
For the development of a more direct conversion of cocaine into a cis-2,5-pyrrolidine 
derivative, ozonolysis of anhydroecgonine methyl ester 21 was investigated.  As illustrated in 
Scheme 1.10, confiscated grade (-)-cocaine•HCl 19 was refluxed in 0.8N hydrochloric acid to 
afford the ecognine 35 in 99% yield.28   
 
Scheme 1.10:  Synthesis of R-(-)-anhydroecgonine methyl ester 
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Subsequent dehydration with phosphorus oxychloride and concomitant esterification using 
methanol afforded the methyl ester 21 in 85% yield.   
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1.5.2.  Initial Studies Directed toward (+)-225H 
 
In Scheme 1.11, the nitrogen atom of the methyl ester 21 was demethylated and protected 
as an ethyl carbamate 33 with a yield of 99%.   
 
Scheme 1.11: Initial Studies Directed Toward (+)-225H 
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The carbon-carbon double bond of 33 was cleaved by ozonolysis at -78 ºC with a subsequent 
reductive workup with triphenylphosphine to afford the tricarbonyl compound 36 with a yield of 
66% with a specific rotation of [α]D25 = +25.7 (c = 1.0, EtOAc).  Selective protection of the 
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aldehyde moiety in 36 was achieved by using trimethyl orthoformate catalyzed by cerium (III) 
chloride heptahydrate.  This afforded acetal 34 in a 79% yield with a specific rotation of [α]D25 = 
+0.98 (c = 1.0, EtOAc).  The α-ketoester moiety in 34 underwent reduction with sodium 
borohydride and concomitant oxidative cleavage with sodium periodate to furnish the aldehyde 
37 in a 69% yield.  However, the aldehyde proved to be labile toward epimerization in which 
purification by chromatography led to a mixture of diastereomers.  Even though epimerization 
occurred the synthesis was continued to establish the methodology for olefination.  The C2-n-
pentyl side chain was constructed by Wittig olefination of aldehyde 37.  The acetal moiety in 37 
was hydrolyzed to furnish the aldehyde 38 with a 58% yield.  The C5 side chain was constructed 
using the same Wittig olefination synthesis to furnish the diene 39 in 40% yield.  This led to a 
sufficiently complex mixture of products due to epimerization at C2. Hydrogenation of the 
olefinic side chains would reduce the complexity of the molecule to furnish a pyrrolidine 31.  
Finally, deprotection of the ethyl carbamate 31 with 33% HBr in AcOH should afford the cis-
pyrrolidine 225H (31).  Further investigation revealed that the α-ketoester was also unstable and 
sensitive to epimerization.  Subsequent preparation of 36 and 34 gave inconsistent optical 
rotations.   
 
1.5.3.  Retrosynthetic Approach to (+)-225H 
 
Due to epimerization of 36 and 34 a different synthetic approach was developed for the 
synthesis of (+)-225H utilizing the (+)-2-tropinone (20) approach via a silyl enol ether 
intermediate (Scheme 1.12) and the Wittig olefination methodology.   
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Scheme 1.12:  Retrosynthetic approach via silyl enol ether 
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The chiral building block, (+)-2-tropinone (20), was revisited in order to revise the procedure for 
the cis-2,5 disubstituted pyrrolidine building block.  The instability of the methyl enol ether 28 
was envisaged to be avoided by preparation of the silyl enol ether 40.29  The retrosynthetic 
approach for the preparation of enantiopure cis-2,5-disubstituted pyrrolidine is outlined in 
Scheme 1.12.  The strategy was to employ the deprotection of the 2,5-disubstituted pyrrolidine 
31 to afford the amphibian alkaloid 225H (32).  The C5-n-pentyl side chain of 32 would be 
constructed by a Wittig olefination sequence followed by hydrogenation of the olefinic side 
chain to furnish the pyrrolidine 31.  The ester moiety of 41 would undergo reduction to aldehyde 
42.  The construction of the C2-n-hexyl side chain of 32 would utilize the same Wittig 
olefination sequence and olefinic side chain hydrogenation procedures to afford 41.  Oxidative 
cleavage and subsequent reductive workup of 40 followed by diazomethane would furnish 29.  
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The ethyl carbamate 27 would be converted into the silyl enol ether 40.  Cocaine 19 undergoes 
degradation followed by N-demethylation and protection as the ethyl carbamate to afford ethyl 
carbamate 2-tropinone 27. 
 
1.5.4.  Synthesis of (+)-225H 
 
The ethyl carbamate protected 2-tropinone 27 was converted into the silyl enol ether 40 
using sodium hydride and tert-butyl dimethyl silyl chloride at 0 ºC in 93% yield (scheme 1.13) 
with a specific rotation of [α]D25 = -49.6 (c = 0.6, MeOH).29 
   
Scheme 1.13:  Synthesis of silyl enol ether 
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The double bond of the silyl enol ether 40 was cleaved by ozone at -78 ºC and concomitant 
reductive workup with triphenylphosphine.  Then the reaction mixture was treated with CH2N2 to 
furnish the enantiopure cis-2,5-disbustituted pyrrolidine 29 in 33% yield over 3 steps with a 
specific rotation of [α]D = +4.57 (c = 0.2, MeOH) (Scheme 1.14).27b,29 
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Scheme 14:  Synthesis of (+)-225H 
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To avoid epimerization at C2 the n-hexyl side chain of 32 was constructed by a Wittig 
olefination sequence to afford the alkene 43 in 35% yield followed by hydrogenation of 
the olefinic side chain to greatly reduce the molecular complexity to furnish the 
pyrrolidine 41 in 60% yield with a specific rotation of [α]D25 = -12.0 (c = 0.6, EtOAc).  
The reduction of the ester 41 with DIBAL-H gave the aldehyde 42 in 91% yield.  
Construction of the C5 n-pentyl side chain utilized the same Wittig olefination sequence 
to afford the alkene 44 in 47% yield.  The olefinic side chain of 44 underwent 
hydrogenation to furnish pyrrolidine 31 in 64% yield with a specific rotation of [α]D25 = 
+9.26 (c = 0.6, EtOAc).  Finally, deprotection of the ethyl carbamate with 33% HBr in 
AcOH afforded the cis-pyrrolidine 225H (32) in 84% yield with a specific rotation of 
[α]D25 = +15.6 (c = 0.4, EtOAc). 
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 In summary, we have developed the first enantioselective synthetic route that 
exploits the natural stereochemistry inherent to cocaine for the synthesis of enantiopure 
cis-2,5-pyrrolidine based alkaloids.  Both (+)-2-tropinone (20) and R-(-)-anydroecgonine 
methyl ester (21), derived from cocaine, were readily converted into the cis-2,5-
pyrrolidine building blocks 29 and 36, respectively.  The enantiopure building blocks 
were ideally suited for the construction of more complex alkaloids due to the asymmetry 
of the appendages and the orthogonal reactivity of the functional groups.  The utility of 
(+)-2-tropinone (20) as a chiral building block was demonstrated by the 9-step synthesis 
of (+)-cis-pyrrolidine 225H (32).  This approach will be effective for providing other 
natural and non-natural derivative for structure-activity studies and will be the subject of 
future investigations. 
 
1.6.  Conclusion 
 
The development of the first enantioselective synthetic route to cis-2,5-pyrrolidine 
based alkaloids exploiting the natural stereochemistry inherent to cocaine has been 
developed.  The desired cis-2,5-pyrrolidine was prepared from the (-)-cocaine desired 
intermediate, (+)-2-tropinone (20), in 9-steps.  The enantiopure building block, (+)-2-
tropinone (20) is well-suited for the construction of more complex alkaloids due to the 
asymmetry of the appendages and the orthogonal reactivity of the functional groups.  
This approach will be effective for providing pyrrolidine ring systems for the synthesis of 
other natural and non-natural derivatives for future investigations and structure-activity 
studies. 
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1.7.  Experimental Section 
 
 
General Methods 
 
 All chemicals were purchased from Aldrich Chemical Company unless otherwise 
noted.  Anhydrous toluene, tetrahydrofuran (THF), dichloromethane (CH2Cl2), and 
methanol (MeOH) were purchased from Mallinckrodt Baker, Inc and were used under 
nitrogen without any further purification.  Thin layer chromatography (TLC) 20 x 20 cm 
glass plates precoated with 250 µm silica gel were purchased from Sorbent Technologies 
and used to monitor reactions via visualization with short-wave UV light, iodine, 
potassium permanganate, phosphomolybdic acid (PMA), 2,4-dinitrophenyl hydrazine or 
Dragondorff’s reagent.  Chromatography is in reference to flash column chromatography 
on silica gel (Silica Gel 60, 230-400 mesh).  High-pressure hydrogenations were carried 
out on a Parr apparatus.  Proton and carbon NMR were recorded on a Varian-Gemini 400 
and 500 MHz nuclear magnetic resonance spectrometer, respectively at ambient 
temperature in deuterated chloroform from Cambridge Isotope Laboratories, Inc.  1H 
NMR chemical shifts are reported in δ values (ppm) with tetramethylsilane (TMS), 
employed as the internal standard.  13C NMR chemical shifts are reported in δ values 
(ppm) with chloroform-D (CDCl3, 77.0 ppm), employed as the internal standard.  Optical 
rotations were measure on Autopol III autopolarimeter at the sodium D line (2 mL 
samples cell).  Elemental analyses were obtained from Atlantic Microlabs, Inc. 
 31
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8-Methyl-8-azabicyclo[3.2.1]octan-2-one (20)27 
Confiscated (-)-cocaine hydrochloride 19 (34.0 g, 100 mmol) in concentrated 
hydrochloric acid (276 mL) was refluxed for 24 h.  The reaction mixture was allowed to 
come to room temperature, diluted with deionized water (255mL) and extracted with 
Et2O (2 x 127mL) to remove the benzoic acid.  The aqueous layer was evaporated until 
dryness under the vacuum.  The solid was further dried under vacuum with an oil bath at 
100ºC for 24 h.  This afforded crude (-)-anhydroecgonine (19.2 g, 94%) without further 
purification was used in the next step. 
To the finely powder acid (5.16 g, 25.3 mmol) from the previous crude step were 
added Na2CO3 (7.62 g, 72 mmol) and DMAP (91.5 mg, 0.75 mmol), and the flask was 
sealed under nitrogen.  To the flask dried CH2Cl2 (110 mL) was added followed by the 
addition of diphenylphosphorylazide (DPPA) (7.77 mL, 0.036 mmol).  The reaction 
mixture was stirred vigorously for 48 h.  The solvent was removed under vacuum.  The 
resulting residue is dissolved in deionized H2O (32 mL).  A solution of  1N HCl (181 
mL) was carefully added to the solution and the mixture was heated to reflux in oil bath 
at 120 ºC until CO2 and N2 evolution ceased (~35 mins.).  The aqueous HCl was removed 
under vacuum and the residue was made basic (~PH = 9.5-10) with saturated Na2CO3.  
The aqueous layer was extracted with CH2Cl2 (3 x 150 mL).  The organic layers were 
combined and dried over Na2SO4.  The solvent was removed under vacuum.  The 
resulting liquid was purified using the Kugelrohr (vacuum bulb to bulb distillation).  This 
afforded 19 (1.11g, 31%, 3 steps) as a colorless liquid.  1HNMR (400 MHz, CDCl3) δ 
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1.58-1.72 (m, 3H), 2.06-2.18 (m, 4H), 2.20-2.28 (m, 1H), 2.34 (s, 3H), 3.15-3.25 (m, 
2H). 
 
N
EtO2C
O
 
2-Oxo-8-azabicyclo[3.2.1]octane-8-carboxylic acid ethyl ester (27)30 
To a solution of 20 (0.643 g, 4.62 mmol), and K2CO3 (382 mg, 2.31 mmol) in 
toluene (8 mL) was added ethyl chloroformate (2.20 mL, 23.1 mmol).  The reaction 
mixture was heated to reflux for 24 h.  The solvent was removed under vacuum and the 
resulting residue was dissolved in deionized H2O (9 mL).  The aqueous layer was 
extracted with CH2Cl2 (3 x 9 mL).  The organic layers were combined and dried over 
Na2SO4.  The solvent was removed under vacuum and the residue was purified by flash 
chromatography (SiO2, 3:7 CH2Cl2/hexane) to yield 26 (0.514 g, 80%) as a pale yellow 
oil.  [α]20D -15.4 (c 0.4, MeOH).  1HNMR (400 MHz, CDCl3) δ 1.23 (t, J = 6.8 Hz, 3H), 
1.78-1.84 (m, 3H), 2.17-2.22 (m, 3H), 2.35-2.45 (m, 2H), 4.10-4.14 (m, 2H), 4.40 (s, 
1H), 4.47 (s, 1H).  13C NMR (400 MHz, CDCl3) δ 14.6, 30.6(2), 32.5(2), 52.8, 61.5, 64.1, 
154.3, 205.7.  Anal. Calcd. for C10H15NO3:  C, 60.90; H, 7.67; N, 7.10.  Found:  C,  
60.90; H, 7.67; N, 7.10.
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R-(-)-anhydroecgonine methyl ester (21)28 
A solution of confiscated grade(-)-cocaine hydrochloride 19 (15.0 g, 44.4 mmol) 
in 0.8 N hydrochloric acid (200 mL) was heated to reflux for 24 h.  The solution was 
cooled to room temperature, and extracted with Et2O (200 mL).  The aqueous layer was 
evaporated under vacuum to dryness.  The solid was further dried under the vacuum at 
100 ºC for 24 h.  This afforded crude ecognine 35 which without further purification was 
used in the next step.  
To the finely powdered solid 35, POCl3 (60 mL) was added and the mixture was 
heated to reflux for 2.5 hours.  Excess POCl3 was removed under reduced pressure and 
the residue was chilled in a dry ice-acetone bath.  Methanol (60 mL) was added to the 
residue and the mixture was brought back to room temperature by swirling.  Methanol 
was removed under reduced pressure.  The residue was dissolved in H2O (100 mL) and 
heated with a saturated ammonium hydroxide solution with NaCl.  The aqueous layer 
was extracted with CH2Cl2 (2 x 100 mL).  The organic layers were combined and dried 
over K2CO3, filtered and concentrated to dryness.  The residue was purified by flash 
chromatography (SiO2, 5% MeOH in EtOAc) to afford 20 (5.80 g, 85% yield) as a pale 
yellow oil.  1HNMR (400 MHz, CDCl3) δ 1.36-1.41 (m, 1H), 1.69-1.76 (m, 2H), 2.00-
2.07 (m, 3H), 2.23 (s, 3H), 2.50 (d, J = 19.6 Hz, 1H), 3.12 (t, J = 5.2 Hz, 1H), 3.64-3.68 
(m, 3H),  6.70 (s, 1H).  13C NMR (400 MHz, CDCl3) δ 29.2, 30.7, 33.5, 35.2, 50.5, 56.0, 
57.6, 133.1, 134.9, 165.4. 
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N-Ethoxycarbonyl-2-methoxycarbonyl-8-azabicyclo[3.2.1]oct-2-ene (33)31 
To a stirred solution of R-(-)-anhydroecgonine methyl ester 21 (6.1 g, 34 mmol), 
and K2CO3 (4.65g) in toluene (130 mL) under nitrogen, ethyl chloroformate (32 mL, 337 
mmol) was added.  The solution was heated to reflux for 24 h.  The solvent was removed 
under reduced pressure and the residue was dissolved in H2O (100 mL).  The aqueous 
layer was extracted with CH2Cl2 (3 x 100 mL).  The organic layers were combined, dried 
over Na2SO4, and the solvent was removed under reduced pressure.  The residue is 
purified by flash chromatography (SiO2, 1:4 EtOAc/hexane) to afford 33 (6.16 g, 99%) as 
a pale yellow oil.  [α]D25 -82.0 (c 1.0, MeOH).  1HNMR (400 MHz, CDCl3) δ 1.11-1.17 
(m, 3H), 1.52 (s, 1H), 1.81-2.09 (m, 4H), 2.76 (s, 1H), 3.62-3.67 (m, 3H), 3.99-4.07 (m, 
2H), 4.30 (s, 1H), 4.78 (s, H), 6.66 (s, 1H).  13C NMR (400 MHz, CDCl3) δ 14.6, 30.2, 
34.3, 34.8, 51.4, 51.7, 52.9, 61.0, 136.2, 136.7, 154.2, 165.4.  Anal. Calcd. for 
C12H17NO4:  C, 60.24; H, 7.16; N, 5.85.  Found:  C, 60.24; H, 7.16; N, 5.85. 
 
N
CO2Et
O
CO2CH3O
 
(2R,5S)-Ethyl 2-(2-methoxy-2-oxoacetyl)-5-(2-oxoethyl)pyrrolidine-1-carboxylate (36) 
Ozone was bubbled through a solution of 33 (4.47 g, 18.7 mmol) in CH2Cl2 (40 
mL) at -78 ºC until a slight blue color persisted.  The mixture was flushed with nitrogen 
for 10 minutes.  Then Ph3P (9.80 g, 37.4 mmol) was added to the solution and the 
mixture stirred overnight.  The solvent was evaporated to dryness under reduced pressure 
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and the residue was purified by flash column chromatography (SiO2, EtOAc/hexane, 1:1) 
to afford 36 (5.15 g, 66%) as an oil.  [α]D25 +25.7 (c 1.0, EtOAc).  1HNMR (400 MHz, 
CDCl3) δ 0.95-1.09 (m, 3H), 1.47-1.56 (m, 1H), 1.76-1.88 (m, 1H), 2.04-2.21 (m, 1H), 
2.38-2.51 (m, 1H), 2.81-3.00 (m, 1H), 3.71 (s, 3H), 3.86-3.93 (m, 2H), 4.17-4.23 (m, 
1H), 4.77-4.86 (m, 1H), 9.60 (s, 1H).  13C NMR (400 MHz, CDCl3) δ 14.2, 27.2, 31.2, 
48.2, 53.0, 61.6, 61.9, 63.1, 154.2, 160.8, 192.11, 200.6.  Anal. Calcd. for C12H17NO6·1 
1/2 H2O:  C, 49.06; H, 6.69; N, 4.77.  Found:  C, 49.27; H, 6.30; N, 4.80. 
 
N
CO2Et
O
CO2CH3H3CO
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(2S,5R)-Ethyl 2-(2,2-dimethoxyethyl)-5-(2-methoxy-2-oxoacetyl)pyrrolidine-1-
carboxylate (34) 
 
To a solution of aldehyde 36 (2.52 g, 9.29 mmol) and CeCl3·7H2O (3.60 g, 9.66 
mmol) in CH3OH (50 mL), HC(OCH3)3 (10 mL, 82.2 mmol) was added.  The reaction 
was stirred for 30 minutes at room temperature then quenched with saturated NaHCO3 
(10 mL).  The reaction mixture was extracted with EtOAc (2 x 40 mL), washed with 
brine and dried over Na2SO4.  The solvent was evaporated to dryness under reduced 
pressure and the residue was purified by flash chromatography (SiO2, 1:1 EtOAc/hexane) 
to afford 34 (2.0 g, 69%yield) as an oil.  [α]D25 +0.98 (c 1.0, EtOAc).  1HNMR (400 
MHz, CDCl3) δ 0.90-1.05 (m, 3H), 1.39 (s, 1H), 1.60 (s, 1H), 1.70-1.80 (m, 3H), 1.91-
2.08 (m, 2H), 3.04 (s, 6H), 3.61 (s, 2H), 3.78-3.84 (m, 3H), 4.67 (d, J = 31.6 Hz, 1H).  
13C NMR (400 MHz, CDCl3) δ13.8, 20.4, 22.0, 36.5, 51.0, 53.3, 55.3, 54.6, 59.8, 62.8, 
102.1, 154.6, 161.0, 200.2. 
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(2S,5R)-Ethyl 2-(2,2-dimethoxyethyl-5-formylpyrrolidine-1-carboxylate (37) 
 CH3OH (6 mL) was added dropwise to a solution of acetal 34 (2.0 g, 6.4 mmol) 
and NaBH4 (600 mg, 16 mmol) in THF (60 mL) at room temperature under a nitrogen 
atmosphere.  The reaction mixture was stirred for 30 minutes and then cooled to 0 ºC.  
(CH3)2CO (4 mL), H2O (30 mL) and Et2O (50 mL) were added to the reaction mixture at 
0 ºC and stirred for 15 minutes.  NaIO4 (4.0 g, 19 mmol) was added to the reaction 
mixture at 0 ºC and stirred for 1 h and at room temperature for 20 minutes.  The reaction 
was quenched with brine (80 mL), extracted with EtOAc (2 x 40 mL), dried over Na2SO4 
and evaporated to dryness.  This afforded a crude oil 37 (0.90 g, 69 % yield) which 
without further purification was used in the next step. 1HNMR (400 MHz, CDCl3) δ 1.12-
1.24 (m, 3H), 1.53-2.13 (m, 6H), 2.14-3.40 (m, 6H), 3.99-4.43 (m, 5H), 9.39 (s, 1H).   
 
N
CO2Et
O
 
 
(2S,5R)-Ethyl 2-(2-oxoethyl)-5-(pent-1-enyl)pyrrolidine-1-carboxylate (38) 
The aldehyde 37 was dissolved in toluene (20 mL) and added to a previously 
prepared solution of (n-butyl) triphenylphosphonium bromide and t-BuOK in toluene (57 
mL) and stirred for 1.5 h.  The reaction mixture was stirred at room temperature for 8 h.  
EtOAc (80 mL) and a solution of Na2S2O3 (38 mL) was added to quench the reaction.  
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The reaction mixture was extracted with EtOAc (2 x 80 mL), washed with brine, dried 
over Na2SO4 and evaporated to dryness.  The residue was dissolved in acetone (10 mL) 
and p-toluenesulfonic acid monohydrate (38 mg, 0.2 mmol) was added to the solution 
and stirred for 1 h.  The solvent was evaporated and the residue was dissolved in CH2Cl2 
(mL), washed with saturated NaHCO3 solution, dried over Na2SO4 and evaporated to 
dryness under vacuum.  The residue was purified by flash chromatography (SiO2, 2:3 
EtOAc/hexane) to afford 38 (0.93 g, 58% yield). 
 
N
CO2Et  
(2S,5R)-Ethyl 2-(hex-2-enyl)-5-(pent-1-enyl)pyrrolidine-1-carboxylate (39) 
 The aldehyde 38 (37.5 mg, 0.148 mmol) was dissolved in THF (2 mL) and added 
to a previously prepared solution on (n-butyl) triphenylphosphonium bromide and nBuLi 
(0.15 mL, 0.37 mmol) in THF (3 mL) that was stirred at room temperature for 1.5 h.  The 
combined reaction mixture was stirred at room temperature overnight.  EtOAc (10 mL) 
and Na2S2O3 solution (5 mL) was added to the reaction mixture and extracted with 
EtOAc (2 x 10 mL), washed with brine, dried over Na2SO4 and evaporated to dryness 
under reduced pressure.  The residue was purified by flash chromatography (SiO2, 1:4 
EtOAc/hexane) to afford 39 (0.12 g, 40% yield).  1HNMR (400 MHz, CDCl3) δ 0.90 (t, J 
= 2.4 Hz, 6H), 1.17-1.48 (m, 8H), 1.54-1.74 (m, 2H), 1.82-2.04 (m, 7H), 2.55 (s, 1H), 
3.86 (s, 1H), 4.06-4.12 (m, 2H), 5.27-5.48 (m, 4H).  13C NMR (400 MHz, CDCl3) 13.9, 
14.3(2), 23.5(2), 31.6, 34.9(2), 39.2, 55.7, 60.9, 58.9, 125.9, 128.7, 130.7, 139.0, 155.7.  
MS (ESI) m/z 293.4 (M). 
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(1R,5R)-Ethyl 2-(tert-butyldimethylsilyloxy)-8-azabicyclo[3.2.1]oct-2-ene-8-
carboxylate (40)29  
 
 NaH (70 mg, 0.58 mmol) was suspended in dry THF (4 mL) under nitrogen at 0ºC 
with ice-NaCl bath.  A solution of compound 27 (115 mg, 3 mmol) in dry THF (1 mL) 
was added dropwise and continued stirring at 0 ºC for 2 h.  Then TBSCl (1.0 M in THF, 
1.2 mL, 1.2 mmol) was added dropwise at 0 ºC.  The reaction mixture was allowed to 
continue stirring overnight.  At 0 ºC, H2O (5 mL) was added slowly.  The solution was 
extracted with Et2O (3 x 10 mL).  The organic portions were combined, dried over 
MgSO4 and evaporated to dryness.  The residue was purified by flash column 
chromatography (SiO2, hexane gradient, CH2Cl2) to afford 40 (169 mg, 93% yield) as a 
colorless oil.  [α]D25 -49.6 (c 0.6, MeOH).  1HNMR (400 MHz, CDCl3) δ 0.14-0.17 (m, 
6H), 0.93 (s, 9H), 1.25 (t, J = 7.2 Hz, 3H), 1.56-1.76 (m, 4H), 1.98-2.13 (m, 3H), 4.09-
4.17 (m, 2H), 4.34 (s, 1H), 4.49 (s, 1H).  13C NMR (400 MHz, CDCl3) -4.10(2), 14.9, 
25.8, 26.1(3), 29.4, 31.4, 34.4, 52.2, 57.5, 61.1, 97.35, 154.7.  MS (ESI) m/z 312.3 (M + 
1).  Anal. Calcd. for C16H29NO3Si:  C, 61.69; H, 9.38; N, 4.50.  Found:  C, 61.86; H, 
9.61; N, 4.38.   
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(2R,5S)-1-Ethyl 2-methyl 5-(2-oxoethyl)pyrrolidine-1,2-dicarboxylate (29)  
Ozone was bubbled through a solution of the TBS enol 40 (4.62 g, 14.8 mmol) in 
40 mL CH2Cl2 at -78 ºC until a slight blue color persisted.  The mixture was flushed with 
nitrogen for 10 minutes.  Then Ph3P (4.28 g, 16.3 mmol) was added to the solution and 
the mixture stirred overnight.  The solvent was evaporated to dryness.  The residue was 
triturated with 2N HCl (20 mL) and the aqueous layer was extracted with Et2O (3 x 25 
mL).  The combined organic layers were dried over MgSO4 and evaporated under 
reduced pressure to afford an oil that was used directly in the next step without further 
purification. 
 To a stirred solution of the crude oil in Et2O (25 mL) at 0 ºC, CH2N2 was passed 
through the solution until a yellow color persisted.  Nitrogen was then passed through the 
reaction mixture for 30 minutes.  The cold bath was removed and the solvent was 
removed under reduced pressure.  The residue was purified by flash column 
chromatography (SiO2, hexane gradient, Et2O, hexane) to afford 29 (1.19 g, 33%) a 
colorless oil.  [α]D25 +4.57 (c 0.2, MeOH).  1HNMR (400 MHz, CDCl3) δ 1.18-1.27 (m, 
3H), 1.70 (d, J = 5.2 Hz, 1H), 1.97-2.01 (m, 2H), 2.16-2.28 (m, 2H), 2.55-2.72 (m, 1H), 
3.74 (s, 3H), 4.08-4.43 (m, 4H).  13C NMR (400 MHz, CDCl3) δ 14.8, 29.2, 30.5, 48.7, 
54.1, 59.7, 60.1, 61.7, 173.6, 201.2.  MS (ESI) m/z 266.2 (M + Na).  Anal. Calcd. for 
C11H17NO5·1/4 H2O:  C, 53.32; H, 7.12; N, 5.65.  Found:  C, 53.00; H, 7.19; N, 5.32. 
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(2R,5S)-1-Ethyl 2-methyl 5-(hex-2-enyl)pyrrolidine-1,2-dicarboxylate (43) 
CH3CH2CH2CH2PPh3Br (5 g, 12 mmol) was suspended in dry THF (40 mL) 
under nitrogen at room temperature.  t-BuOK (1.0 M in THF, 11.3 mL, 11.3 mmol) was 
added dropwise to the solution and stirred for 2 h.  The aldehyde 29 (1.2 g, 4.9 mmol) 
was dissolved in THF (5 mL) and added dropwise to the reaction mixture.  The combined 
reaction mixture was stirred for 8 h, then EtOAc (20 mL) and Na2S2O3 solution (10 mL) 
was added.   The reaction mixture was extracted with EtOAc (2 x 20 mL), washed with 
brine, dried over Na2SO4 and evaporated to dryness.  The residue was purified by flash 
column chromatography (SiO2, hexane ) to afford 43 (485 mg, 35%) an oil.  1HNMR 
(400 MHz, CDCl3) δ 0.91 (t, J = 24.4 Hz, 3H), 1.77-1.47 (m, 7H), 1.68-1.78 (m, 1H), 
1.88-2.21 (m, 5H), 2.45-2.73 (m, 1H), 3.74 (s, 3H), 3.93-4.37 (m, 3H), 5.16-5.61 (m, 
2H).   
 
N
O
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(2R,5R)-1-Ethyl 2-methyl 5-heyxlpyrrolidine-1,2-dicarboxylate (41) 
A solution of 43 (485 mg, 1.7 mmol), 10% Pd/C (108 mg) in EtOH (20 mL) was 
hydrogenated using a hydrogen balloon for 2 h.  The catalyst was removed by filtration 
through a pad of celite.  The solvent was removed under reduced pressure and the residue 
was purified by flash column chromatography (SiO2, hexane) to afford 41 (292 mg, 60%) 
an oil.  [α]D25 -12.0 (c 0.6, EtOAc).  1HNMR (400 MHz, CDCl3) δ 0.85 (t, J = 5.2 Hz, 
 41
3H), 1.12-1.42 (m, 11H), 1.64-2.19 (m, 6H), 3.69 (s, 3H), 3.91-4.32 (m, 4H).  13CNMR 
(400 MHz, CDCl3) δ 14.3, 14.8, 22.8, 26.6(2), 28.4, 29.4, 29.6, 32.0, 52.4, 59.6, 61.3, 
61.4, 156.3, 173.5.  MS (ESI) m/z 286.4 (M + 1), 308.5 (M + Na).  Anal. Calcd. for 
C15H27NO4:  C, 63.13; H, 9.54; N, 4.91.  Found:  C, 63.64; H, 9.92; N, 4.74. 
 
N
O
CO2Et  
(2R,5R)-Ethyl 2-formyl-5-hexylpyrrolidine-1-carboxylate (42) 
 Ester 41 (180 mg, 0.63 mmol) was dissolved in toluene (3 mL) under nitrogen at  
-78 ºC.  DIBAL-H (1.0 M in toluene, 0.69 mL, 0.69 mmol) was added dropwise over 45 
minutes.  The reaction mixture was allowed to continue stirring at -78 ºC for 15 minutes 
and then the cold bath is removed.  Et2O (10 mL), H2O (4 mL) and 15% NaOH (6 mL) 
were added.  The mixture was extracted with Et2O (2 x 20 mL) and the combined organic 
layers were dried over MgSO4 evaporated to dryness.  The residue was purified by flash 
chromatography (SiO2, hexane) to afford 42 (146 mg, 91%) an oil.  1HNMR (400 MHz, 
CDCl3) δ 0.87 (t, J = 6.0 Hz, 3H), 1.13-1.45 (m, 14H), 1.53-2.23 (m, 3H), 3.68-3.74 (m, 
1H), 3.91-4.35 (m, 3H), 9.58 (s, 1H). 
 
N
CO2Et  
(2R,5R)-ethyl 2-hexyl-5-(pent-1-enyl)pyrrolidine-1-carboxylate (44) 
CH3CH2CH2CH2PPh3Br (570 mg, 1.4 mmol) was suspended in dry THF (20 mL) 
under nitrogen at room temperature.  t-BuOK (1.0 M in THF, 1.3 mL, 1.3 mmol) was 
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added dropwise to the solution and stirred for 2 h.  The aldehyde 42 (150 mg, 0.57 mmol) 
was dissolved in THF (5 mL) and added dropwise to the reaction mixture.  The combined 
reaction mixture was stirred for 8 h, then EtOAc (10 mL) and Na2S2O3 solution (5 mL) 
was added.   The reaction mixture was extracted with EtOAc (2 x 10 mL), washed with 
brine, dried over Na2SO4 and evaporated to dryness.  The residue was purified by flash 
column chromatography (SiO2, hexane) to afford 44 (79.6 mg, 47%) an oil.   
 
N
CO2Et  
(2R,5S)-ethyl 2-hexyl-5-pentylpyrrolidine-1-carboxylate (31) 
A solution of 44 (80 mg, 0.27 mmol), 10% Pd/C (31 mg) in EtOH (10 mL) was 
hydrogenated using a hydrogen balloon for 2 h.  The catalyst was removed by filtration 
through a pad of celite.  The solvent was removed under reduced pressure and the residue 
was purified by flash column chromatography (SiO2, hexane) to afford 44 (51.6 mg, 
64%) an oil.  [α]D25 +9.26 (c 0.6, EtOAc).  1HNMR (400 MHz, CDCl3) δ 0.88 (t, J = 7.2 
Hz, 6H), 1.18-1.47 (m, 19H), 1.58-2.26 (m, 6H), 3.58-4.34 (m, 4H).  13CNMR (400 MHz, 
CDCl3) δ 14.2(2), 14.9, 22.8(2), 26.2, 26.5, 29.6(3), 32.0(2), 35.9(2), 60.7, 160.4.  MS 
(ESI) m/z 298.6 (M + 1).  Anal. Calcd for C18H35NO2:  C, 72.68; H, 11.86; N, 4.71.  
Found:  C, 72.52; H, 11.76; N, 4.69. 
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(2R, 5S)-2-hexyl-5-pentylpyrrolidine 
A solution of 44 (25 mg, 0.10 mmol) in 33% HBr/AcOH (2 mL) was stirred at rt 
under nitrogen for 48 h.  EtOAc (20 mL) and sat. NaHCO3 solution was added to the 
mixture until the solution was basic.  The mixture was extracted with EtOAc (2 x 10 mL), 
washed with brine, dried over Na2SO4.  The solvent was removed under reduced pressure 
and the residue was purified by flash chromatography (SiO2, EtOAc/MeOH/Et3N, 
40:2:1).  The purified oil was dissolved in CH2Cl2 (5 mL) and washed with sat. NaHCO3 
solution (5 mL) and the solvent was evaporated to dryness under reduced pressure to 
afford 32 (16 mg, 84%) a light yellow oil.  [α]D25 +15.6 (c 0.4, MeOH).  1HNMR (400 
MHz, CDCl3) δ 0.89-0.86 (m, 6H), 1.21-1.40 (m, 19H), 1.42-1.53 (m, 2H), 1.76-1.90 (m, 
2H), 2.89-2.98 (m, 2H).  13CNMR (400 MHz, CDCl3) δ 14.0, 14.1, 22.6(2), 27.0, 27.2, 
29.3(2), 30.2, 31.7(2), 35.1(2), 59.6(2).  MALDI-TOF-MS 226.3390 [M+ + H].  Anal. 
Calcd. for C15H31N:  C, 79.92; H, 13.86; N, 6.21.  Found:  C, 72.52; H, 11.76; N, 4.69. 
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CHAPTER 2 
 
Synthesis of Diaryl Ether Analogues of BAY 59-3074 as Potential 
Therapeutics for Marijuana Abuse 
 
2.1.  Abstract 
 
The search for potent cannabinoid receptor partial agonist as potential marijuana 
addiction therapeutic agents has led to an investigation of the synthesis of diaryl ether hybrid 
analogues of BAY 59-3074.  A series of 2-(3-alkyl-5-hydroxyphenoxy)-6-(trifluoromethyl) 
benzonitriles, 3-(2-cyano-3-(trifluoromethyl)phenoxy) phenylalkanoates, and (3- 
(benzyloxy)phenoxy)-6-(trifluoromethyl) benzonitriles were synthesized and evaluated in vitro 
for CB1 affinity.  The olivetol diaryl ether analogue was the most potent ligand of the alkyl 
series, but the diaryl ester analogues exhibited modest affinity for CB1 receptors.  The most 
potent compound of the series was the 2-(3-(benzyloxy)phenoxy)-6-(trifluoromethyl) 
benzonitrile. 
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2.2.  Introduction 
 
2.2.1.  Drug Addicition 
 
Cannabis (marijuana) is one of the most commonly abused recreational drugs self-
administered by smoking.  Cannabis related disorders are becoming a major public health issue.  
In 2006, 25% of Americans age 12 and over abused marijuana at least once prior to the year of 
being surveyed.1  According to the NIDA, a study showed that 10.9% of 8th graders, 23.9% of 
10th graders, and 32.4% of 12th graders had abused marijuana at least once in the year prior to 
being surveyed.2   
Cannabis has been used by various civilizations as a therapeutic agent with advances as 
an analgesic, nausea, appetite stimulation and a host of other medical applications.3-5  Historical 
evidence suggests that Emperor Shen Nung 3000 B.C. was the first to recognize that cannabis 
had potential medicinal properties, which was used as an analgesic.6  In India, the effects of 
smoking cannabis were associated with faith and were used as anesthetics and aphrodisiacs.7  
Cannabis is obtained from the Indian hemp Cannabis Sativa L. and contains a variety of natural 
cannabinoids.8   
Cannabinoids are terpenophenolic compounds with a structural relationship similar to (-)-
trans-∆9-tetrahydrocannabinol (∆9-THC) 1 or compounds with the ability to bind to cannabinoid 
receptors.  To date, at least 66 cannabinoids have been isolated from the cannabis plant.9  The 
most prevalent natural cannabinoids that have been studied extensively are THC 1, cannabidiol  
(CBD) (2), and cannabinol (CBN) (3) (Figure 2.1). 
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Figure 2.1:  Plant Cannabinoids  
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THC 1 is the major psychoactive constituent of marijuana.  This psychoactive constituent 
has high lipid solubility and low water solubility.6  THC 1 has analgetic and 
neuroprotective properties with equal affinity for the two subtypes of the cannabinoid 
receptor, and produces the “high” associated with the binding to the CB receptor in the 
brain.   
In 1963, the structure and stereochemistry of cannabidiol (2) and THC 1 were first 
determined, but cannabinoids were first discovered in the 1940’s with the structure 
identification of CBD 2 and CBN 3.9   Unlike THC 1, cannabidol (2) is not psychoactive 
and possess medical benefits such as relieving convulsion, inflammation, anxiety and 
nausea.10  It is an allosteric antagonist at the brain cannabinoid receptor that alters 
psychoactive effects of THC 1 and is selective for central nervous system (CNS) 
cannabinoid receptor subtype (CB1 subtype) over receptor subtypes found in the immune 
system (CB1 subtype).10  Cannabinol (3) is the main product in the degradation of THC 1 
and is found to be mildly psychoactive and has the same affinity at CB2 as cannabidol 
(2).11 
Currently, there are no effective treatments for marijuana abuse.  Due to 
marijuana dependence being a major public health issue the development of new 
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medications for treatment of marijuana abuse is essential.  The physiological and 
behavioral effects of cannabinoids have been studied extensively and suggest that a 
cannabinoid antagonist could be useful as treatment for marijuana abuse.12-14  There is an 
urgency for the development of pharmacotherapies to treat marijuana addiction while 
understanding the mechanism of marijuana action on the central nervous system (CNS).  
 
2.2.2  Cannabis, Addiction and the Cannabinoid Hypothesis 
 
Some drugs of abuse have reinforcing effects, which can lead to abuse and/or 
addiction. Addictive drugs have reinforcing effects which include activation of the 
reinforcement mechanism which causes the release of dopamine (4) in the nucleus 
accumbens.15   
 
Figure 2.2:  Structure of dopamine 
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The abusive burden surrounding marijuana is produced by those reinforcing properties, 
which lead to repeated marijuana use.13  Addiction is thought to be caused by unpleasant 
physiological effects upon discontinued use of an abused substance in which tolerance 
can develop.  It is believed that tolerance is produced to compensate for the intoxicated 
condition of the body.15  The abused drug acts to disturb the homeostatic mechanisms in 
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the brain in which these mechanisms produce effects opposite to the drug of abuse by 
compensating for the disturbance.15  Cannabis has both psychoactive and physiological 
effects.  These effects include short term physical and neurological effects such as 
increased heart rate, lowered blood pressure, short term memory, and psychomotor 
impairments.13,15  
Drug seeking behaviors are mediated by the release of dopamine (4).  The more 
dopamine that is present allows for the increased activation of dopamine receptors 
(Figure 2.3).15 
  
THC Binding to THC Receptors 
 
 
            Figure 2.3.  THC binds to the THC receptors (magenta) on the neighboring terminal, which 
                  sends a signal to the dopamine terminal to release more dopamine.16 
 
With the increased dopamine present there is an increase in the cAMP production inside 
the post synaptic cell, which alters the normal activity of neurons.16  Besides drugs of 
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abuse, stress and other salient stiumuli mediate dopamine release.  Therefore, dopamine 
release does not suggest that drugs of abuse are activating the natural reward system.  
Drug addiction can not only be linked to the activation of the reward system mediated by 
the dopamine in the nucleus accumbens.  With this in mind, dopamine’s role in the CNS 
can not be taken too lightly. 
 According to the proposed “Cannabinoid Hypothesis”, the endocannabinoid 
physiological system control system (EPCS) has a potential role in the regulation of the 
rewarding effects of abused drugs through the neurobiological mechanisms.17  Drug 
addiction is mediated by a variety of neurotransmitters in the brain circuit.  The 
cannabinoid receptors are abundantly present in the brain.  These receptors use retrograde 
signaling, which is associated with the inhibition of transmission at the synapse by 
neurotransmitter suppression.  Due to this abundant presence in the brain retrograde 
signaling of these cannabinoids are limitless and may explain the behavioral effects 
associated with cannabis.17  The retrograde messengers inhibit a host of transmitters such 
as dopamine, serotonin, GABA, and acetylcholine.14,17  The endocannabinoid 
transmission plays a significant role in the dependence/withdrawal to abused substances 
and drug seeking behavior through mediation of motivation.15 
Molecular and neurobiological studies on the basis of the physiological and 
neurobehavioral effects of marijuana and cannabinoids have lagged behind other natural 
addictive drugs such as cocaine, opium and tobacco.  The CB1 receptor has gained 
interest due to its presence within the CNS and association with the brain-reward circuits 
of the mesocorticolimbic dopamine systems which are located in the substantia nigra and 
ventral tegmental.12,14,17  Many drugs of abuse elevate dopamine levels and the ability of 
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these CB1 receptor antagonist or inverse agonists to attenuate these elevations has 
suggested their potential application as pharmacotherapies for treating drug abuse 
disorders.12,14  Therefore, the administration of a drug that blocks the CB1 receptors 
abolishes the high produced by smoking marijuana. 
The homeostatic disturbance in the body can be restored by cannabinoid ligands.  
The cannabinoid antagonist, Rimonabant, shows promise in the downregulation of drug 
abuse and alcoholism, and smoking cessation.15  Although the CB1 receptors have the 
ability to modulate effects of drug abuse, the exact mechanism of their interaction was 
uncertain.15  The effects of cannabinoids and marijuana use are mediated by the 
activation of cannabinoid receptors.  There are two well characterized cannabinoids, CB1 
and CB2, whose identities have been elusive due to the study plant natural product, THC 
1.  Due to the discovery of CB1 and CB2 investigation into endocannabinoids function 
has blossomed.  One potential role that is of focus is the ability of CB1 receptors to 
modulate effects of drug abuse.  In addition, medical use of cannabis can beneficially aid 
in the treatment of nausea and vomiting5, hunger stimulation in chemotherapy and AIDs 
patients18, glaucoma, and as an analgesic.6 
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2.2.3.  Cannabinoid Receptors and G Protein Coupling 
 
Mammalian tissue has 2 types of cannabinoid receptors:  CB1 and CB2.  Both 
cannabinoid receptors are transmembrane G-protein coupled receptors.14,19  CB1 
receptors are predominately found at nerve terminals and mediate inhibition of 
transmitter release.20  They are predominately located in the brain, adipose tissue, muscle, 
liver, GI tract and pancreas.  CB2 receptors are present in the CNS, but in a much lower 
concentration than CB1 receptors.21  CB2 receptors are found in immune cells and 
modulate cytokine release.21  They are predominately located in the T-cells, B-cells, 
spleen, tonsils, and monocytes.  There has been long and great debate over the 
physiological and behavioral effects of cannabinoids through nonspecific and specific 
interactions.  Evidence has suggested that these receptors and G proteins are pre-coupled.   
 
 
   Figure 2.4:  Structure of G-protein coupled receptors CB1 and CB2 
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These G protein-coupled receptors shown above include an extracellular N-terminal 
domain, 7 transmembrane helices with intervening loops that extend both intra- and 
extracellularly, and a cytoplasmic C-terminal domain.22  The G protein-coupled receptors 
(GPCRs), also known as seven-transmembrane domain receptors (7TM receptors), sense 
molecules outside the cell and activate inside signal transduction pathways.  
The G protein-coupled receptors are involved in many diseases, and are also the 
target of around half of all modern medicinal drugs.23  Some examples of their 
physiological roles include behavioral, mood and immune system regulation.  There are 
two principal signal transduction pathways involving the G-protein coupled receptors: the 
cAMP signal pathway and the phosphatidylinositol signal pathway.24  
The G-proteins are bound to receptors in an inactive state.  Ligands or signal 
mediators can activate these G protein-coupled receptor by creating a conformational 
change in the receptor.  Upon ligand recognition, there is a conformational change in the 
receptor and the G-protein is activated.  Once activation occurs the G-protein can detach 
from the receptor and either activate another G-protein by exchanging its bound 
guanosine diphosphate (GDP) for a guanosine triphosphate (GTP) or return back to its 
inactive state.  It is believed that a receptor molecule exists in a conformational 
equilibrium between active and inactive biophysical states.25  
The binding of ligands to the receptor may shift the equilibrium toward the active 
receptor states.26  There are two types of ligands that exist: agonists and or antagonists.  
Agonist are a class of ligands that favor the active states.29  Within the agonist ligands 
there are low efficacy agonist deemed partial agonists.  Among antagonists there are both 
antagonist and ligands that exhibit inverse agonist pharmacological profiles.  Inverse 
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agonists favor the inactive states.29  How exactly the active and inactive states differ has 
yet to be determined.  To date, the characterization of these receptors have relied upon 
ligand receptor interactions.30-31   
 
2.2.3.1.  CB1 Receptor Ligands 
 
There are a five main chemical classes of cannabinoids:  natural cannabinoids, 
synthetic cannabinoids, eicosanoids, 1,5-diarylpyrazoles, and aminoindoles.  Natural 
“classical” cannabinoids are dibenzopyran derivatives.30-31  Synthetic “nonclassical” 
cannabinoids are bicyclic and tricyclic analogues of ∆9-THC 1.  However, eicosanoids 
“endocannabinoids” have a completely different structure.30-31  The four classes of 
cannabinoid ligands that represent the essential characteristics of CB1 receptor agonist 
include classical cannabinoid, ∆9-THC 1; nonclassical cannabinoid,  
CP 55,940 (5); aminoindole WIN 55,2112-2 (6) and the endogenous cannabinoid, 
anandamide (7).31   
 
Figure 2.5:  Structure of CB1 Receptor Agonists 
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CB1 receptor agonists are responsible for cAMP production inhibition32, calcium influx 
inhibition33, potassium channel activation34, MAP Kinase pathway activation35, and an 
increase in intracellular dopamine levels in the brain.12,14,36-39   
 In rat brain tissue, there was the discovery of a high affinity and 
pharmacologically distinct class of cannabinoid receptors.19a  This discovery led the 
search for a variety of natural endogenous ligands in the brain that have the ability to bind 
to this cannabinoid receptor.  These endocannabinoids are produced within the body and 
can activate cannabinoid receptors.  Upon the identification of the two cannabinoid 
receptors, the endogenous ligands anandamide (7) and 2-arachidonyl glycerol ether (2-
AG) (8) were isolated.   
 
Figure 2.6:  Structure of Endogenous Ligand 
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Anandamide (7) has a similar potency as THC 1 at the CB1 receptor and acts as a partial 
agonist.  However, 2-AG 8 has the ability to bind to both the CB1 and CB2 receptors and 
act as a full agonist at both and has a higher concentration in the brain than anandamide 
(7).40-41  Anandamide (7) and 2-AG 8 are the most extensively studied endogenous 
cannabinoids, but in order to understand the endocannabinoids system synthetic ligands 
were necessary. 
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Synthetic cannabinoids are useful in the determination of structure-activity 
relationships (SAR) of the endocannabinoid system.  There was a need to find new 
synthetic cannabinoids with an increase in therapeutic activity and limited adverse side 
effects.  However, the question remained if cannabinoid compounds could be used in 
pain suppression.  In the 1980’s, Pfizer focused on these novel analgesic compounds.  
Early attempts at cannabinoid based analgesics and antiemetics led to the development of 
levonantradol (9) (Figure 2.7).   
 
Figure 2.7:  Structure of Levonantradol 
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This cannabinoid compound was more potent than THC 1, easier to administer, but had 
too many side effects.42  From these early studies, CP55-940 (5), a synthetic analog of ∆9-
THC 1 was created and lead to the important discovery of CB1 receptor in 1988.   
CP 55,940 (5) mimics the effects of THC 1 and is a full agonist at both CB1 and CB2 
receptors.31b  This synthetic analog allowed for radioligand binding assays that were not 
possible for ∆9-THC 1 due to the lipophilicity, which led to non-specific binding during 
in vitro experiments.  The development of this analog led to further advancement in the 
cannabinoid field and also pushed for the need of selective agonists and antagonists for 
CB1 and CB2 receptors.  SR141716A 10 (figure 2.8) commonly referred to as 
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Rimonabant was the first potent and selective antagonist (inverse agonist) of CB1 
receptors.  
 
Figure 2.8:  Structure of SR 141716A 
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Rimonabant 10 was developed as an anti-obesity drug used for blockade of CB1 receptor 
that cause “munchies” among marijuana users.12-14 
The aminoalkylindole derivative, WIN-55212-2 (6) is also a potent cannabinoid 
receptor agonist.  This potent agonist has both analgesic43 and neuropathic44 properties 
and anti-inflammatory.45  WIN-55212-2 (6) is a full agonist at the CB1 receptor with a 
higher affinity than THC 1 for the CB1 receptor.46   The in vitro SARs of WIN-55212-2 
(6) led to the development of new agonists.  Nabilone 11 (Figure 2.9) is a synthetic 
analogue of ∆9-THC 1 and is licensed for medical use.   
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Figure 2.9:  Structure of Nabilone 
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Nabilone (11) mimics THC 1 and is used therapeutically as an analgesic and antiemetic.  
This compound is not considered a narcotic by the World Health Organization (WHO) 
because it lacks the euphoric and recreational potential.  In 1985, the U.S. Food and Drug 
Administration (FDA) approved nabilone (11) for treating chemotherapy-induced nausea 
and vomiting5, anorexia and as an appetite stimulant for AIDS patients.18   
Due to the extensive work on cannabinoids there is an increased interest in 
creating more medically, beneficial synthetic cannabinoids.  Cannabinoid SAR data has 
indicated that the side chain and the phenolic hydroxyl groups are pertinent in CB1 
receptor recognition.  Synthetic cannabinoids can target one or both receptors and can act 
or block, which allows more therapeutic options than medical marijuana.   
 
2.2.4.  Binding Affinity and Inhibition Constant 
 
Neurotransmitters, inhibitors, activators, and substrates are considered ligands.  The 
cellular response is obtained by the ligand acting as a signal molecule to a target protein 
by an intermolecular force like ionic bonds, hydrogen bonds, and Van der Waals forces.47  
Ligands have the ability to bind and form complexes with molecules to initiate a cellular 
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response that alters the chemical conformation of the receptor protein.  A receptor is 
considered an agonist when a ligand binds to it and alters the function creating a 
response.29  The alteration of the receptor is characterized by the amount of the 
physiological response and the concentration of the agonist required to activate the 
physiological response.  If an agonist can maximally stimulate the receptor it is 
considered a full agonist, but if an agonist can only partially activate the physiological 
response it is considered a partial agonist.29  However, if the physiologic response is not 
activated by binding of the ligand to the receptor it is then deemed an antagonist. 
The binding affinity is defined as the interaction between ligand and it’s binding 
sites (strength of binding).  Generally, if a ligand has a high affinity the intermolecular 
force is greater, and has longer time at the receptor compared to low affinity.29  In 
addition, a high binding affinity implies a low concentration of a ligand to maximally 
occupy a receptor and trigger a physiological response.  On the other hand, a low binding 
affinity implies a high concentration of ligand to maximally occupied and the maximum 
physiological response to the ligand is achieved.29  Binding affinities are determined 
using a radiolabeled ligand, which are radioisotope labeled compounds and are used in 
vivo studies as tracers in positron emission tomography (PET) studies and for in vitro 
binding studies.   
Binding assays are done by using a radioligand usually an agonist in a low 
concentration either at or below the dissociation constant, Kd.  The binding specificity is 
determined in the presence of the range of the concentration competing non-radio 
labelled compound usually an antagonist to measure the  potency through binding 
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competition at the radio labelled ligand.  Kd is the dissociation constant of the radioligand 
for a particular receptor.   
The inhibition constant, Ki, or the half maximal inhibitory constant, IC50,  
qualitatively indicates the potency for drug binding.  IC50 represents the concentration to 
produce half of the maximal inhibition.  It measures the amount of drug that is necessary 
to inhibit biochemical pathways by half.  For drug candidates, Ki is the measurement of 
the effectiveness of a compound to inhibit certain biochemical pathways.  The IC50 is 
converted to Ki by using the Cheng-Prusoff equation.48 
 
K i =
Km
[S]
IC50
[1]
 
 
 [S] is the substrate concentration and Km is the substrate’s affinity for an enzyme.  The Ki 
or IC50 values display the binding affinity that the ligand binds to the receptor.  
Experimental values of the IC50 are variable based on radioligand concentration whereas 
Ki is an absolute value.    
  
2.2.5.  Ligand Design Strategy 
 
 CB1 antagonists have been shown to block the effects of THC 1 and are also 
devoid of abuse liability.  However, current antagonists exhibit inverse agonist activity 
eliciting the opposite response to an agonist.  Thus making CB1 antagonist unsuitable for 
drug addiction treatment due to the potential side effects that include nausea, decreased 
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food intake and body weight, increased nocieptive sensitivity, and increased anxiety and 
depression, which is associated with Rimonabant (53).50-53  An alternative to this 
approach is the development of partial agonist as therapy.  Partial agonist stimulate 
dopamine, raise basal dopamine levels without euphoric effects and the abuse liability is 
diminished due to a weaker efficacy.  The development of a useful cannabinoid partial 
agonist has application for the treatment of cannabinoid and/or psychostimulant 
addiction.  The compounds CB25 (12), and BAY59-3074 (13) exhibit low efficacy 
agonist profiles both in vitro and in vivo as compared to THC 1.   
 
Figure 2.10:  Cannabinoid partial agonist 
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These compounds are less potent than full agonist CP 55,940 (5) and WIN 55212-2 (6) 
by stimulation of [35S] GTPγS binding.  Our strategy will focus on the synthesis and 
development of new cannabinoid partial agonist ligands with less efficacy than THC 1 
based upon the structures of the lead compounds CB25 (12) and BAY 59-3074 (13) that 
are envisaged to exploit the favorable properties of each molecule.    CB25 (12) exhibits a 
high affinity (Ki = 5 nM) at the CB receptors.54  However, CB25 (12)  is very 
hydrophobic (ClogP = 6.2)55 and is unlikely to be a viable drug candidate.  It is desired to 
improve the hydrophilicity (ClogP < 5) while taking advantage of the high potency of 
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CB25 (12) by replacing the amide side chain with an aryl moiety similar to ring-A of 
BAY 59-3074 (13).   
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BAY 59-3074 (13) exhibits modest affinity (Ki = 55 nM)56 and displays good 
lipophilicity (ClogP = 4.77)55 compared to CB25 (12) and its analogues are more likely to 
be viable drug candidates.  We want to synthesize these novel BAY 59-3074-CB25 
hybrid analogues and characterize the binding affinity at the cannabinoid receptors in 
which the in vitro data will suggest potential for potent receptor affinity.    
The ligand design strategy will utilize SARs for a series of lead compounds that 
will optimize potency and hydrophilicity.  The diaryl ether derivative will serve as a 
template for SAR studies of novel partial agonist. 
 
Figure 2.11:  Diaryl Ether Derivative Template 
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Structural modifications will include modifications of the two side chains, R1 and R2.  
Studies will provide SAR data to identify potent classes of CB receptor ligands.  These 
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diaryl ether derivatives of BAY 59-3074 are the first class of compounds that will be 
prepared based on the basic scaffold since no SAR data for has been collected for BAY 
59-3074 (13) at the CB receptors.  The diaryl ether core will be derived from 
commercially available activated aryl fluoride and a 3-benzyloxyphenol.  Microwave 
assisted uncatalyzed coupling reactions will be utilized to generate the diaryl ether 
scaffold in high yield.57  Debenzylation under hydrogenolysis conditions will provide the 
diaryl ether phenol.  The sulfonate ester will be achieved by using phase transfer catalysis 
to afford BAY 59-3074.58   
 
2.3.  Results and Discussion 
 
2.3.1.  Synthesis of 5-Alkylbenzene-1,3-diols 
 
Commercially available diols included resorcinol, orcinol and olivetol.  The 
propyl and hexyl alkylresorcinols were also available through Japanese suppliers, but 
were too expensive (>$100 for milligram quantities).  Therefore, the alkylresorcinols 
were synthesized using an approach developed by the Makriyannis group.57  The initial 
approach involved the Grignard reaction between 3,5-dimethoxybenzaldehyde (14)  and 
the appropriate alkylmagnesium halide to obtain the corresponding alcohol 15 (Scheme 
2.1). 
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Scheme 2.1:  Synthesis of 5-Alkylbenzene-1,3-diols59 
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The alcohol 15 was then deoxygenated under catalytic hydrogenolysis using 10%Pd/C 
and a hydrogen balloon in glacial acetic acid at 60 ºC to furnish the resorcinol dimethyl 
ether 16.  The dimethyl ether groups of 16 were deprotected with BBr3 at -78 ºC to give 
the desired 5-alkylbenzene-1,3-diol 17.  This procedure was employed to synthesize the 
propyl, butyl, and hexyl benzene-1,3-diols in 99%, 88%, and 99% yield, respectively.   
The 5-ethylbenzene-1,3-diol 19 was synthesized using a procedure from the 
Linusson group (Scheme 2.2).60  The carbonyl of 3,5-dihydroxyacetophenone (18) was 
reduced under catalytic hydrogenation (1 atm) conditions with 10%Pd/C in 4% HCl at 
room temperature to furnish the ethylresorcinol 19 in 72% yield. 
 
Scheme 16:  Synthesis of 5-ethylbenzene-1,3-diol60 
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2.3.2.  Synthesis of BAY 59-3074 and Alkyl Analogues 
 
A variety of natural products and biologically interesting compounds contain a 
diaryl ether motif.57  Diaryl ethers have been synthesized by coupling phenols to electron 
deficient aryl halides through SNAr-based addition reactions with microwave irradiation 
within 5-10 minutes.57  The synthesis of the diaryl ether scaffold is outlined in Scheme 
2.3.  The appropriate benzoxyphenol 21 was synthesized by the monobenzylation of the 
desired resorcinol derivative 20 using NaH and benzyl bromide (BnBr) at room 
temperature.  The diaryl scaffold was synthesized from commercially available 2-fluoro-
6-(trifluoromethyl) benzonitrile and the appropriate alkylbenzoxyphenol 21 through 
microwave assisted uncatalyzed coupling reactions following the approach taken by the 
Wang group.57  Debenzylation of the benzoxyphenol 22 was established under 
hydrogenolysis conditions  with 10% Pd/C in EtOH at 45 ºC to provide the diaryl ether 
phenol 23. 
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Scheme 2.3:  Synthesis of BAY 59-3074 Alkyl Analogues 
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The binding affinities of the 2-(3-hydroxy-5-alkylphenoxy)-6-(trifluoromethyl) 
benzonitriles summarized in Table 2.1, were determined by the ability of the compounds 
to displace bound radiolabeled ligands binding in rat brain tissue.  The binding affinites 
of the novel BAY 59-3074 alkyl analogues were determined at the cannabinoid receptor 
(CB1) by inhibition of [3H]SR141716A since it is selective for the CB1 receptor.  Even 
though CB2 receptors may be present in the brain their concentration is minimal 
compared to the CB1 receptors.  Our focus is the development of CNS compounds so it 
was deemed unnecessary to determine the CB2 affinities at this time. 
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Table 2.1:  In Vitro binding data at CB1 and [3H]SR141716A inhibition  
 
YO
CN
F3C
X
 
 
Cmpd. Code # X Y ClogPa [
3H]SR141716A 
(CB1) Ki (nM)b 
 
CB1c 
(10 µM) 
 
CB1c 
(100 µM) 
 
23b ARN 156 OH CH3 4.39 23,055±3217 16 30 
23c ARN 167 OH CH2CH3 4.92  21 37 
23d ARN 180 OH CH2CH2CH3 5.45  24 60 
23e ARN 191 OH CH2(CH2)2CH3 5.98  35 94 
23f ARN 158 OH CH2(CH2)3CH3 6.50 293±107 39 41 
23g ARN 190 OH CH2(CH2)4CH3 7.03  TBA TBA 
13 BAY  
59-3074 
H SO2(CH2)3CF3 4.77 55d 61 65 
aThe ClogP values were calculated using CS ChemDraw Ultra 10.0.   bAll the values are  
mean ± SEM of    three experiments.   cBinding affinities at CB1 receptor measured 
as % inhibition.  dSee reference 56. 
 
 It was desired to improve hydrophilicity (ClogP < 5) in order to maximize blood 
brain barrier permeability according to Lipinski’s rules.61  However, as the alkyl chain 
increased in length the hydrophilicity decreased and the lipophilicity increased.  The most 
potent of the alkyl series was the olivetol derivative 23f.  In general, the alkyl series were 
less potent than BAY 59-3074 (Ki = 55 nM)56.  The alkyl series 23c-23g (ClogP = 4.39 - 
6.55)55 was more lipophilic compared to the BAY 59-3074 (ClogP = 4.77)55, but 23b was 
an improvement in the hydrophilicity.  Even though 23b showed an improvement in 
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hydrophilicity its potency was extremely low in comparison to 23f.  Therefore, it was 
desired to synthesize the BAY 59-3074 for comparison and a series of esters to determine 
if the electron density can enhance the inhibition of the BAY 59-3074 analogues at the 
CB1 receptors.   
The diaryl ether phenol 23a undergoes phase transfer catalysis with 4,4,4-
Trifluoro-butane-1-sulfonyl chloride, 45% NaOH and tetrabutylammonium bromide at 
0ºC to afford BAY 59-3074 (13) in 40% yield (Scheme 2.4).62 
 
Scheme 2.4:  Synthesis of BAY 59-307462 
 
OHO
CN
F3C
23a
NaOH/Bu4NBr
CH2Cl2, 0°C OO
CN
F3C
S CF3
O O
F3C S Cl
O O
40% 13  
 
The binding affinity for the sulphonate ester 13 is presented in Table 2.1.  The BAY 59-
3074 has modest binding affinity (Ki = 55 nM)56 and a greater affinity compared to the 
alkyl series reported in Table 2.1.  Therefore, the syntheses of the ester analogues were 
attractive targets. 
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2.3.3.  Synthesis of BAY 59-3074 Ester Analogues 
 
The same phase transfer catalysis utilized for BAY 59-3074 was employed to 
synthesize the diaryl ether ester analogues (Scheme 2.5).   
 
Scheme 2.5:  Synthesis of Diaryl Ether Esters Analogues 
 
OHO
CN
F3C 23a
R' Cl
O
NaOH/Bu4NBr
CH2Cl2, 0°C
R' = methyl, ethyl, propyl, butyl, pentyl
OO
CN
F3C 24
R'
O
61 - 78%
 
 
The diaryl ether phenol 23a undergoes phase transfer catalysis with the appropriate acid 
halide, 45% NaOH and tetrabutylammonium bromide at 0 ºC to afford the desired diaryl 
ether ester analogue 24. 
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Table 2.2:  [3H]SR141716A uptake inhibition at CB1 
 
OO
CN
F3C R
'
O
 
 
 
Compound Code # 
 
R’ 
 
ClogPa 
 
CB1c 
(10µM) 
 
CB1c 
(100µM) 
 
24a ARN 199 CH3 3.91 18 45 
24b ARN 200 CH2CH3 4.43 25 34 
24c ARN 201 CH2CH2CH3 4.96 25 25 
24d ARN 202 CH2(CH2)2CH3 5.49 25 49 
24e ARN 203 CH2(CH2)3CH3 6.02 7 19 
aThe clogP values were calculated using CS ChemDraw Ultra 10.0.   bAll the values are  
 mean ± SEM of    three experiments.   cBinding affinities at CB1 receptor measured 
 as % inhibition. 
 
Upon evaluation of the ester series, there was significant improvement of the 
hydrophilicity 24a-24e (ClogP 3.92 – 6.02)55 compared to the alkyl series 23b-23g 
(ClogP 4.39 – 7.03)55.  The alkyl chain in the ester series increased in length the 
hydrophilicity decreased and the lipophilicity increased.  The butyl ester, 68d, exhibited 
modest percent inhibition at the CB1 receptor in comparison to the other synthesized 
esters.  By comparing the affinities of 24d and 24e there is a significant difference 
derived from the addition of a single carbon atom.  This difference suggests that there is a 
size maximum in the ester moiety.  Therefore, it was desired to compare the synthesized 
compounds that exhibited modest to high percent inhibition at the CB1 receptor.  In 
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addition to comparing the synthesized compounds, we choose to include 22a and 23a 
intermediates to observe the percent inhibition to focus on potential lead compounds.  
 
2.3.4.  Evaluation of BAY 59-3074 Analogues 
 
These novel BAY 59-3074-CB25 hybrid analogues were synthesized and the 
binding affinity at the cannabinoid receptors was determined (Table 2.3).  
 
Table 2.3:  Comparison of [3H]SR141716A uptake inhibition at CB1 
OR2O
CN
F3C
OO
CN
F3C R
3
O
R1
22a R1 = H, R2 = Bn
23a R1 = H, R2 = H
23f R1 = (CH2)4CH3, R
2 = H
24d R3 = (CH2)3CH3
 
 
Compound Code # 
 
ClogPa 
 
CB1c 
(10µM) 
 
CB1c 
(100µM) 
 
13 
BAY  
59-3074 
 
4.77 61 65 
22a AS 109 6.24 49 56 
23a ARN 142 3.89 3 37 
23f ARN 158 6.50 39 41 
24d ARN 202 5.49 25 49 
aThe clogP values were calculated using CS ChemDraw Ultra 10.0.   bAll the values are  
 mean ± SEM of    three experiments.   cBinding affinities at CB1 receptor measured 
 as % inhibition. 
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Table 2.3 serves as a survey of each class of analogues and the most potent ligand 
of the series.  Although our focus lies in developing a compound with improved 
hydrophilicity, the benzyl ether intermediate 22a showed some promise.  In evaluating 
the compounds, 22a was deemed the most potent with inhibition values greater than the 
alkyl and ester analogues of each series.  However, the potency is less than that of the 
BAY 59-3074.  Improvement was made upon the hydrophilicity with the ester analogue 
series, but the potency was lower than 13.  Future SAR studies will focus on using the 
benzyl ether 22a as a lead compound for the development of novel CB1 ligands.  
 
2.3.5.  Synthesis of BAY 59-3074 Benzyl Ether Analogues 
 
Using the benzyl ether 22a as a lead compound a variety of benzyl analogues with 
electron withdrawing and donating groups were synthesized (Scheme 2.6).  The binding 
affinity at CB receptors is currently under investigation and will be reported in due 
course. 
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Scheme 2.6:  Synthesis of BAY 59-3074-CB25 hybrid benzyl analogues 
 
F3C
CN
O OH
Z
X
YNaH
DMF, RT
F3C
CN
O O
X
Y
23a 25
25a X = H Y = 4-Cl
25b X = H Y = 4-CF3
25c X = H Y = 4-OCH3
25d X = H Y = 4-CH3
25e X = 3-Cl Y = 4-Cl
25f X = H Y = 4-Br
25g X = H Y = 4-F
 
 
2.4.  Conclusion 
 
A series of BAY 59-3074 analogues were synthesized to obtain a new class of 
CB1 receptor ligands.  A series of alkyl ligands 23b-23g , ester ligands 24a-24e, and the 
benzyl ether intermediate 22a were synthesized and evaluated.  The alkyl series produced 
the olivetol derivative 23f as a potential lead compound suggesting that an alkyl chain of 
5 carbons can lead to a potent CB1 ligand.  Within the ester series, there was 
improvement of the hydrophilicity 24a-24e compared to the alkyl series 23b-23g.  The 
valeryl ester derivative 24d showed modest affinity at the CB1 receptors.  Comparison of 
24d and 24e gave insight into the chain length that can be applied to modifiying these 
potential lead compounds.  The significant decrease in affinity led to the formulation that 
there is a size limitation for the ester series.  The benzyl ether intermediate 22a exhibited 
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the highest affinity over both the alkyl and ester series.  Future SAR studies will focus on 
the benzyl ether 22a as a lead compound for the development of novel CB1 ligands.  
 
2.5.  Experimental Section 
 
General Methods 
  
All chemicals were purchased from Aldrich Chemical Company unless otherwise 
noted.  Anhydrous toluene, tetrahydrofuran (THF), dichloromethane (CH2Cl2), and 
methanol (MeOH) were purchased from Mallinckrodt Baker, Inc and were used under 
nitrogen without any further purification.  Thin layer chromatography (TLC) 20 x 20 cm 
glass plates precoated with 250 µm silica gel were purchased from Sorbent Technologies 
and used to monitor reactions via visualization with short-wave UV light, iodine, 
potassium permanganate, phosphomolybdic acid (PMA), 2,4-dinitrophenyl hydrazine or 
Dragondorff’s reagent.  Chromatography is in reference to column chromatography on 
silica gel (Silica Gel 60, 230-400 mesh).  High-pressure hydrogenations were carried out 
on a Parr apparatus.  Proton and carbon NMR were recorded on a Varian-Gemini 300 and 
400 MHz nuclear magnetic resonance spectrometer, respectively at ambient temperature 
in deuterated chloroform from Cambridge Isotope Laboratories, Inc.  1H NMR chemical 
shifts are reported in δ values (ppm) with tetramethylsilane (TMS), employed as the 
internal standard.  13C NMR chemical shifts are reported in δ values (ppm) with 
chloroform-D (CDCl3, 77.0 ppm), employed as the internal standard.  Elemental analyses 
were obtained from Atlantic Microlabs, Inc. 
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General Method A:  Preparation of Alkylresorcinols 
 
Gringard Methodology59 
To a stirred solution of 3,5-dimethoxybenzaldehyde (14) (1 equiv.) in THF and 
Et2O at -78 ºC under argon was added  alkylmagnesium halide (1.28 equiv.) dropwise 
over 30 minutes.  The reaction was gradually brought to room temperature and stirred for 
1 h.  The reaction was quenched dropwise by adding saturated aqueous NH4Cl.  The 
reaction was then diluted with EtOAc and brine, and stirred vigorously.  The reaction 
mixture was extracted with EtOAc.  The organic layers were combined, washed with 
brine, dried over MgSO4, and evaporated to dryness under reduced pressure.   
 
Deoxygenation Methodology59 
To a stirred solution of the dimethoxyalcohol 15 (1 equiv.) in glacial acetic acid 
was added 10 % Pd/C (10 wt. %) and the resulting suspension was stirred vigorously 
under a hydrogen atmosphere using a hydrogen balloon overnight at 60 ºC.  Upon 
completion the reaction mixture was diluted with Et2O, brine, and water and filter 
through a pad of celite to remove the catalyst.  The organic layer was separated, diluted 
with water and neutralized by the addition of NaHCO3.  The aqueous layer was extracted 
with Et2O.  The combined organic layers were washed with brine, dried over MgSO4 and 
evaporated under reduced pressure.   
 
 
 
 77
Demethylation Methodology59 
 To a stirred solution of 1-hexyl-3,5-dimethoxybenzene 16 (1 equiv.) in anhydrous 
CH2Cl2 at -78 ºC under an argon atmosphere was added BBr3 (2.5 equiv.) dropwise over 
15 minutes.  Following the addition the reaction mixture was gradually brought to room 
temperature and allowed to continue stirring for 4 h.  The reaction mixture was quenched 
by the addition of MeOH and ice at 0 ºC, the resulting mixture was warmed to room 
temperature, stirred for 40 minutes and the solvent was removed under reduced pressure.  
The residual oil was diluted with EtOAc and the solution was washed with saturated 
aqueous NaHCO3, water and brine.  The organic layer was dried over MgSO4, filtered 
and evaporated under reduced pressure. 
 
General Method B:  Preparation of 2-ethylbenzene-1,3-diol60 
A solution of 3,5-dihydroxyacetophenone 18 (1 equiv.) and 10% Pd/C (50 wt. %) 
in 4% HCl was hydrogenated using a hydrogen balloon overnight.  The reaction mixture 
was filtered through celite, and extracted with Et2O.  The combined organic layers were 
dried over MgSO4 and evaporated to dryness under reduced pressure.   
 
General Method C:  Preparation of monobenzylated 1,3-diols 
 The diol (1 equiv.) in DMF was added dropwise to NaH (1 equiv.) in DMF.  The 
reaction mixture was allowed to stir for 30 minutes at room temperature.  BnBr (1 equiv.) 
in DMF was added dropwise to the reaction mixture and allowed to stir for 2 h at room 
temperature.  Distilled H2O was added and the mixture was extracted with EtOAc.  The 
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organic layers were combined, washed with 0.5 N HCl, washed with brine, dried over 
Na2SO4, and evaporated to dryness under reduced pressure.   
 
General Method D:  Preparation of Diaryl Ethers57 
2-Fluoro-6-(trifluoromethyl)benzonitrile (10 mmol), phenol 21 (10~12 mmol), 
and potassium carbonate (20 mmol) were added to DMSO.  Using a microwave power of 
300-400 W the temperature was ramped from room temperature to the boiling point of 
DMSO.  Upon completion of the reaction, it was cooled to room temperature, put into ice 
water, and extracted with Et2O.  The organic layers were combined, washed with 0.5 N 
HCl, washed with brine, dried over Na2SO4, and evaporated to dryness under reduced 
pressure.   
 
General Method E:  Preparation of Debenzylated Diaryl Ethers 
A solution of 2-(3-(benzyloxy)-5-alkylphenoxy)-6-(trifluoromethyl)benzonitrile 
22 (1 equiv.) and 10% Pd/C (50 wt. %) in EtOH (23 mL) was hydrogenated using a 
hydrogen balloon at 45 ºC.  The reaction mixture was filtered through celite and 
evaporated to dryness under reduced pressure.   
 
General Method F:  Preparation of sulphonic ester, BAY 50-3074 
Under argon, the phenol 23a (0.711 mmol) is dissolved in DCM and 
tetrabutylammonium iodide (0.337 mmol) and 20M NaOH were added and stirred.  At 0 
ºC, 4,4,4-trifluorobutane-1-sulphonyl chloride (0.809 mmol) dissolved in DCM was 
added.  The reaction mixture was allowed to stir for 1 h after the color change at 0 ºC and 
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another 1 h at room temperature.  The reaction mixture was diluted with water and 
extracted with DCM.  The organic layers were collected, washed with brine, and dried 
over MgSO4.   
 
General Method G:  Preparation of Esters 
Under argon, the phenol 23a (0.53 mmol) is dissolved in DCM and 
tetrabutylammonium iodide (0.27 mmol) and 20M NaOH were added and stirred.  At 0 
ºC, the acid halide (0.63 mmol) dissolved in DCM was added.  The reaction mixture was 
allowed to stir for 1 h after the color change at 0 ºC and for another 1 h at room 
temperature.  The reaction mixture was diluted with water and extracted with DCM.  The 
organic layers were collected, washed with brine, and dried over MgSO4.   
 
O O
HO
 
1-(3,5-Dimethoxyphenyl)propan-1-ol (15a)59 
 General Method A.  No further purification to afford 8.38 g (98%) of (15a) as a 
pale yellow oil:  Rf 0.40 (EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ  0.93 (t, J = 
7.6 Hz, 3H), 1.68-1.81 (m, 2H), 3.79 (s, 6H), 4.23 (t, J = 6.4 Hz, 1H), 2.73 (broad s, 1, 
OH), 6.37 (s, 1H), 6.50 (d, J = 2.0 Hz, 2H).  13CNMR (400 MHz, CDCl3) δ 10.1, 31.9, 
56.0(2), 77.8, 98.4, 104.7(2), 147.7, 160.9(2). 
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O O
 
1-Propyl-3,5-dimethoxybenzene (16a)59 
General Method A.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, Et2O/hexane, 1:9) to afford 0.910 g (43%) of (16a) as a pale yellow 
oil:  Rf 0.78 (CH2Cl2/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ  0.98 (t, J = 7.2 Hz, 
3H), 1.67 (q, J = 7.6 Hz, 2H), 2.56 (t, J = 7.2 Hz, 2H), 3.80 (s, 6H), 6.33 (t, J = 2.4 Hz, 
1H), 6.38 (d, J = 2.4 Hz, 2H).  13CNMR (400 MHz, CDCl3) δ  14.1, 24.6, 38.6, 55.4(2), 
97.8, 106.8(2), 145.4, 161.0(2).  
 
HO OH
 
5-Propylbenzene-1,3-diol (17a)59 
 General Method A.  No further purification to afford 0.839 g (99%) of (17a) as 
an amber oil:  Rf  0.48 (EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ  0.92 (t, J = 
7.6 Hz, 3H), 1.60 (q, J = 7.2 Hz, 2H), 2.47 (t, J = 7.6 Hz, 2H), 4.72 (broad s, 1, OH), 6.17 
(s, 1H), 6.24 (d, J = 1.6 Hz, 2H).  13CNMR (400 MHz, CDCl3) δ 14.0, 24.3, 38.1, 100.4, 
108.3(2), 146.0, 159.2(2). 
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O O
HO
 
1-(3,5-Dimethoxyphenyl)butan-1-ol (15b)59 
 General Method A.  No further purification to afford 3.85 g (99%) of (15b) as 
pale yellow oil:  Rf 0.68 (EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ 0.92 (t, J = 
7.2 Hz, 3H), 1.23-1.47 (m, 2H), 1.59-1.79 (m, 2H), 3.77 (s, 6H), 4.57 (t, J = 6.8 Hz, 1H), 
6.35 (td, J = 2.0 Hz, 2.4 Hz, 1H), 6.49 (t, J = 2.4 Hz, 2H).  13CNMR (400 MHz, CDCl3) δ 
14.2, 19.2, 41.3, 55.5(2), 74.6, 99.5, 104.0(2), 147.9, 161.0(2).  
 
O O
 
1-Butyl-3,5-dimethoxybenzene (16b)59 
General Method A.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, Et2O/hexane, 1:9) to afford 1.383 g (39%) of (16b) as a yellow oil:  
Rf 0.89 (EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ 1.00 (t, J = 7.2 Hz, 3H), 
1.42 (sextet, J = 7.6 Hz, 2H), 1.62-1.70 (m, 2H), 2.62 (t, J = 7.6 Hz, 2H), 3.82 (s, 6H), 
6.36 (t, J = 2.4 Hz, 1H), 6.42 (d, J = 2.0 Hz, 2H).  13CNMR (400 MHz, CDCl3) δ 14.2, 
22.7, 33.7, 36.3, 55.3(2), 97.8, 106.7(2), 145.6, 161.0(2).  
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HO OH
 
5-Butylbenzene-1,3-diol (17b)59 
 General Method A.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, Et2O/hexane, 1:9) to afford 1.04 g (88%) of (17b) as an amber oil:  Rf 
0.45 (EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ 0.86 (t, J = 7.6 Hz, 3H), 1.23-
1.32 (m, 2H), 1.43-1.51 (m, 2H), 2.40 (t, J = 7.6 Hz, 2H), 5.43 (broad s, 1, OH), 6.24 (t, J 
= 2.0 Hz, 1H), 6.28 (d, J = 2.4 Hz, 2H).  13CNMR (400 MHz, CDCl3) δ 14.1, 22.5, 33.4,  
35.7, 100.4, 108.3(2), 146.4, 156.8(2).  
 
O O
HO
 
1-(3,5-Dimethoxyphenyl)hexan-1-ol (15c)59 
 General Method A.  No further purification to afford 8.22 g (97%) of (15c) as a 
pale yellow oil:  Rf 0.64 (EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ 0.86 (dt, J = 
3.6 Hz, 6.8 Hz, 3H), 1.25-1.29 (m, 5H), 1.37-1.43 (m, 1H), 1.63-1.77 (m, 2H), 3.78 (s, 
6H), 4.58 (q, J = 7.2 Hz, 1H), 6.35 (t, J = 2.4 Hz, 1H), 6.49 (dd, J = 2.4 Hz, 2.4 Hz, 2H).  
13CNMR (400 MHz, CDCl3) δ 14.2, 22.8, 25.7, 31.9, 39.2, 55.5(2), 74.9, 99.5, 104.0(2), 
147.9, 161.1(2).  
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O O
 
1-Hexyl-3,5-dimethoxybenzene (16c)59 
General Method A.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, Et2O/hexane, 1:9) to afford 1.23 g (32%) of (60c) as a yellow oil:  Rf 
0.38 (EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ 0.89 (t, J = 6.8 Hz, 3H), 1.28-
1.38 (m, 6H), 1.57-1.64 (m, 2H), 2.55 (t, J = 7.6 Hz, 2H), 3.78 (s, 6H), 6.30 (t, J = 2.4 
Hz, 1H), 6.35 (d, J = 2.0 Hz, 2H).  13CNMR (400 MHz, CDCl3) δ  14.3, 22.9, 29.3, 31.5, 
32.0, 36.6, 55.4(2), 97.8, 106.7(2), 145.6, 161.0(2). 
 
HO OH
 
5-Hexylbenzene-1,3-diol (17c)59 
 General Method A.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, Et2O/hexane, 1:9) to afford 1.23 g (99%) of (17c) as a light brown 
oil:  Rf (EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ 0.88 (t, J = 2.4 Hz, 3H), 
1.24-1.28 (m, 6H), 1.55 (t, J = 6.0 Hz, 2H), 2.47 (t, J = 7.6 Hz, 2H), 5.50 (broad s, 1, 
OH), 6.18 (s, 1H), 6.24 (s, 2H).  13CNMR (400 MHz, CDCl3) δ 14.3, 22.8, 29.2, 31.2, 
31.9, 36.0, 100.4, 108.2(2), 146.4, 156.9(2). 
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HO OH
 
5-Ethylbenzene-1,3-diol (19)60 
General Method B.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:4) to afford 1.31 g (72%) of (19) as a colorless oil:  
Rf 0.16 (EtOAc/hexane, 1:4).  1HNMR (400 MHz, CDCl3) δ 1.19 (t, J = 7.6 Hz, 3H), 
2.53 (q, J = 7.6 Hz, 2H), 5.06 (broad s, 2, OH), 6.19 (t, J = 2.4 Hz, 1H), 6.27 (d, J = 2.0 
Hz, 2H).  13CNMR (400 MHz, CDCl3) δ 15.4, 28.9, 100.5, 107.6(2), 135.5, 157.0(2). 
 
HO OBn
 
3-Benzyloxyphenol (21a) 
General Method C.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:5, 1:4) to afford 0.86 g (24%) of (21a) as an amber 
oil:  Rf 0.46 (EtOAc/hexane, 1:4).  1HNMR (400 MHz, (CD3)2CO) δ 4.75 (broad s, 1, 
OH), 5.04 (s, 2H), 6.43 (tt, J = 1.6 Hz, 2.0 Hz, 1H), 6.49 (t, J = 2.4 Hz, 1H), 6.56 (qq, J = 
0.8 Hz, 0.8 Hz, 1H), 7.14 (t, J = 8.4 Hz, 1H), 7.31-7.44 (m, 5H).  13CNMR (400 MHz, 
(CD3)2CO) δ 69.7, 102.6, 106.3, 108.4, 127.8, 128.0(2), 128.7(2), 130.3, 137.8, 158.9, 
160.6. 
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HO OBn
 
3-Benzyloxy-5-methyl-phenol (21b) 
General Method C.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:5, 1:4) to afford 0.995 g (29%) of (21b) as a pale 
yellow oil:  Rf 0.44 (EtOAc/hexane, 1:4).  1HNMR (400 MHz, (CD3)2SO) δ 2.18 (s, 3H), 
5.00 (s, 2H), 6.24 (d, J = 4.4 Hz, 2H), 6.29 (s, 1H), 7.31 (t, J = 4.0 Hz, 3H), 7.35-7.43 (m, 
2H), 9.30 (broad s, 1, OH).  13CNMR (400 MHz, (CD3)2SO) δ 21.3, 69.0, 99.4, 106.4, 
108.9, 127.6(2), 127.7, 128.4(2), 137.4, 139.5, 158.5, 159.6. 
 
HO OBn
 
3-Benzyloxy-5-ethylphenol (21c) 
 General Method C.  The residue was purified by column chromatography (SiO2, 
gradient of hexane) to afford 0.379 g (18%) of (21c) as a yellow oil:  Rf 0.47 
(EtOAc/hexane, 1:4).  1HNMR (400 MHz, (CDCl3) δ 1.21 (t, J = 7.6 Hz, 3H), 2.57 (q, J 
= 7.6 Hz, 2H), 4.61 (broad s, 1, OH), 5.02 (s, 2H), 6.31 (q, J = 2.4 Hz, 1H), 6.44 (s, 2H), 
7.33-7.44 (m, 5H).  13CNMR (400 MHz, (CDCl3) δ 15.5, 29.1, 70.2, 99.7, 107.4, 107.8, 
127.8(2), 128.2, 128.8(2), 137.2, 147.4, 156.7, 160.3. 
 
 86
HO OBn
 
3-Benzyloxy-5-propylphenol (21d) 
 General Method C.  The residue was purified by column chromatography (SiO2, 
gradient of hexane) to afford 0.256 g (19%) of (21d) as a yellow oil:  Rf 0.51 
(EtOAc/hexane, 1:4).  1HNMR (400 MHz, CDCl3) δ  0.93 (t, J = 7.2 Hz, 3H), 1.50-1.66 
(m, 2H), 2.53 (t, J = 7.2 Hz, 2H), 5.02 (s, 2H), 6.23 (d, J = 2.0 Hz, 1H), 6.23-6.47 (m, 
2H), 7.09-7.44 (m, 5H).  13CNMR (400 MHz, CDCl3) δ 13.9, 24.4, 38.2, 70.5, 104.6, 
112.9, 113.0, 127.8(2), 128.4, 128.9(2), 136.6, 146.7, 160.4, 161.9. 
 
HO OBn
 
3-Benzyloxy-5-butylphenol (21e) 
 General Method C.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, 1:9, 1:7, 1:5) to afford 0.409 g (26%) of (21e) as a dark brown oil:  Rf 
0.67 (EtOAc/hexane, 3:7).  1HNMR (400 MHz, (CDCl3) δ 1.03-1.08 (m, 3H), 1.42-1.51 
(m, 2H), 1.64-1.72 (m, 2H), 2.62 (dd, J = 7.6 Hz, 2.0, 2H), 5.07 (s, 2H), 6.38 (d, J = 4.4 
Hz, 1H), 6.44 (s, 1H), 6.48 (d, J = 2.4 Hz, 1H), 6.49 (s, 1H), 7.26-7.53 (m, 5H).  13CNMR 
(400 MHz, (CDCl3) δ 14.3, 22.7, 33.6, 36.1, 70.5, 100.1, 108.4, 108.9, 128.0(2), 128.4, 
129.0(2), 137.3, 146.2, 156.7, 160.3. 
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HO OBn
 
3-Benzyloxy-5-pentyl-phenol (21f) 
General Method C.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:5, 1:4) to afford 0.457 g (31%) of (21f) as a brown 
oil:  Rf 0.53 (EtOAc/hexane, 1:4). 1HNMR (400 MHz, (CD3)2 CO) δ 0.89 (t, J = 6.8 Hz, 
3H), 1.26-1.34 (m, 4H), 1.55-1.63 (m, 2H), 2.49-2.56 (m, 2H), 5.02 (s, 2H), 7.30-7.44 
(m, 5H), 8.21 (broad s, 1, OH).  13CNMR (400 MHz, (CD3)2 CO) δ 13.7, 22.6, 31.1, 31.6, 
36.0, 69.6, 99.8, 106.5, 108.4, 127.7(2), 127.9, 128.6(2), 138.0, 145.3, 158.6, 160.4. 
 
HO OBn
 
3-Benzyloxy-5-hexylphenol (21f) 
 General Method C.  The residue was purified by column chromatography (SiO2, 
gradient of hexane) to afford 0.374 g (21%) of (21f) as a light brown oil:  Rf 0.72 
(EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ 0.95 (dt, J = 2.4 Hz, 4.0 Hz, 3H), 
1.31-1.40 (m, 6H), 1.62 (q, J = 7.6 Hz, 2H), 2.56 (t, J = 8.0 Hz, 2H), 5.03 (s, 2H), 5.75 
(broad s, 1, OH), 6.36 (d, J = 8.8 Hz, 1H), 6.38 (t, J = 2.4 Hz, 1H), 6.50 (d, J = 1.2 Hz, 
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1H), 7.35-7.48 (m, 5H).  13CNMR (400 MHz, CDCl3) δ 14.3, 22.8, 29.2, 31.2, 31.9, 36.2, 
70.2, 99.9, 108.0, 108.6, 127.8(2), 128.2, 128.8(2), 137.1, 146.0, 156.6, 160.1. 
 
OBnO
CN
F3C
 
2-(3-Benzyloxy-phenoxy)-6-trifluoromethyl-benzonitrile (22a)57 
 General Method D.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:10, 1:9, 1:4) to afford 0.325 g (23%) of (22a) as a 
white solid:  Rf 0.60 (EtOAc/hexane, 1:4).  1HNMR (400 MHz, (CD3)3SO) δ 5.16 (s, 2H), 
6.82 (t, J = 8.4 Hz, 1H), 6.94-7.00 (m, 2H), 7.24 (d, J = 11.6 Hz, 1H), 7.33-7.45 (m, 6H), 
7.65 (d, J = 10.0 Hz, 1H), 7.82 (d, J = 10.8 Hz, 1H).  13CNMR (400 MHz, (CD3)3SO) δ 
70.1, 107.2(3), 112.5, 112.8, 120.8(2), 121.1, 127.8(3), 128.1(2), 128.7, 131.2, 135.2, 
137.2, 155.9, 160.9, 161.0.  MS (ESI) m/z 392.2 (M + Na), 387.3 (M + H2O), 370.2 (M + 
1).  Anal. Calcd. For C21H14F3NO2:  C, 68.29; H, 3.82; N, 3.79.  Found:  C, 68.21; H, 
3.77; N, 3.81.   
 
OBnO
CN
F3C
 
2-(3-Benzyloxy-5-methyl-phenoxy)-6-trifluoromethyl-benzonitrile (22b)57 
General Method D.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:5, 1:4) to afford 1.35 g (91%) of (22b) as a pale 
yellow oil:  Rf 0.56 (EtOAc/hexane, 1:5).  1HNMR (400 MHz, (CD3)2CO) δ 2.34 (s, 3H), 
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5.14 (s, 2H), 6.66 (s, 1H), 6.73 (s, 1H), 6.84 (s, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.34 (d, J = 
7.2 Hz, 1H), 7.39 (t, J = 7.2 Hz, 2H), 7.46 (d, J = 7.2 Hz, 2H), 7.65 (d, J = 7.6 Hz, 1H), 
7.82 (t, J = 8.4 Hz, 1H).  13CNMR (400MHz, (CD3)2CO) δ 20.9, 70.1, 104.3(2), 113.2, 
113.5, 120.7(2), 120.8, 121.1, 127.8(2), 128.1, 128.7(2), 135.2(2), 137.3, 141.9, 155.7, 
160.6, 161.7. 
 
 
2-(3-(Benzyloxy)-5-ethylphenoxy)-6-(trifluoromethyl)benzonitrile (22c)57 
General Method D.  The residue was purified by column chromatography (SiO2, 
gradient of hexane) to afford 0.404 g (74%) of (22c) as a pale yellow oil:  Rf 0.71 
(EtOAc/hexane, 1:4).  1HNMR (400 MHz, CDCl3) δ 1.23 (t, J = 7.6 Hz, 3H), 2.63 (q, J = 
7.2 Hz, 2H), 5.04 (s, 2H), 6.53 (t, J = 2.4 Hz, 1H), 6.56 (s, 1H), 6.75 (s, 1H), 7.06 (d, J = 
8.8 Hz, 1H), 7.32-7.44 (m, 2H), 7.53 (t, J = 8.8 Hz, 2H).  13CNMR (400 MHz, CDCl3) δ 
15.4, 29.1, 70.5, 104.5(2), 112.4(2), 112.5, 120.1, 120.2(2), 127.8(2), 128.4, 128.9(2), 
134.0(3), 148.2, 155.4, 160.5, 161.8. 
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2-(3-(Benzyloxy)-5-propylphenoxy)-6-(trifluoromethyl)benzonitrile (22d)57 
General Method D.  The residue was purified by column chromatography (SiO2, 
gradient of hexane) to afford 0.279 g (64%) of (22d) as a pale yellow oil:  Rf 0.63 
(EtOAc/hexane, 1:4).  1HNMR (400 MHz, CDCl3) δ  0.93 (t, J = 7.6 Hz, 3H), 1.60-1.66 
(m, 2H), 2.56 (t, J = 7.2 Hz, 2H), 5.04 (s, 2H), 6.54 (d, J = 1.6 Hz, 2H), 6.73 (s, 1H), 7.05 
(d, J = 8.8 Hz, 1H), 7.32-7.44 (m, 6H), 7.53 (t, J = 8.4 Hz, 1H).  13CNMR (400 MHz, 
CDCl3) δ 13.4, 24.4, 38.2, 70.5, 95.7, 104.6(2), 112.9, 113.0, 115.6, 120.0, 120.1(2), 
127.8(2), 128.3, 128.9(2), 134.0, 136.6, 146.7, 155.3, 160.4, 161.9.  
 
 
2-(3-(Benzyloxy)-5-butylphenoxy)-6-(trifluoromethyl)benzonitrile (22e)57 
General Method D.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane 3:7, CH2Cl2/Hexane 3:7) to afford 0.244 g (36%) of 
(22e) as a colorless oil:  Rf 0.80 (CH2Cl2/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ 
0.94 (t, J = 7.6 Hz, 3H), 1.28-1.41 (m, 2H), 1.56-1.64 (m, 2H), 2.61 (t, J = 6.8 Hz, 2H), 
5.05 (s, 2H), 6.54-6.56 (m, 2H), 6.75 (s, 1H), 7.07 (d, J = 8.8 Hz, 1H), 7.32-7.45 (m, 6H), 
7.53 (t, J = 8.0 Hz, 1H).  13CNMR (400 MHz, CDCl3) δ 14.1, 22.5, 33.4, 35.9, 70.5, 
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104.6(2), 112.6, 112.9, 113.0, 120.1, 120.2(2), 127.8(2), 128.4, 128.9(2), 134.1(2), 136.7, 
146.9, 155.3, 160.4, 161.9. 
 
 
2-(3-Benxyloxy-5-pentyl-phenoxy)-6-trifluoromethyl-benzonitrile (22f)57 
General Method D.  The residue was purified by column chromatography (SiO2, 
gradient of hexane) to afford 0.446 g (72%) of (22f) as a pale yellow oil:  Rf 0.36 
(EtOAc/hexane, 1:9). 1HNMR (400 MHz, (CD3)2 CO) δ 0.88 (dd, J = 3.2 Hz, 6.8 Hz, 
3H), 1.29-1.36 (m, 4H), 1.63 (q, J = 5.6 Hz, 2H), 2.62 (t, J = 8.0 Hz, 2H), 5.14 (s, 2H), 
6.69 (t, J = 2.0 Hz, 1H), 6.75 (t, J = 2.4 Hz, 1H), 6.86 (t, J = 2.0 Hz, 1H), 7.24 (d, J = 8.8 
Hz, 1H), 7.33-7.41(m, 3H), 7.46-7.48 (m, 2H), 7.63 (d, J = 7.6 Hz, 1H), 7.79-7.83 (m, 
1H).  13CNMR (400 MHz, (CD3)2 CO) δ 13.7, 30.9, 31.5, 32.5, 35.8, 70.1, 104.5(2), 
112.7(2), 113.0, 120.6(2), 120.9, 127.8(2), 128.1, 128.7(2), 135.2(2), 137.3, 147.0, 155.6, 
160.7, 161.8. 
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2-(3-(Benzyloxy)-5-hexylphenoxy)-6-(trifluoromethyl)benzonitrile (22g)57 
General Method D.  The residue was purified by column chromatography (SiO2, 
gradient of hexane) to afford 0.491 g (98%) of (22g) as a yellow oil:  Rf 0.49 
(EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ 0.90 (t, J = 5.2 Hz, 3H), 1.31 (s, 
6H), 1.59 (td, J = 2.8 Hz, 6.0 Hz, 2H), 2.60 (t, J = 7.6 Hz, 2H), 5.05 (s, 2H), 6.55 (d, J = 
1.6 Hz, 2H), 6.75 (s, 1H), 7.07 (d, J = 8.4 Hz, 1H), 7.32-7.45 (m, 6H), 7.55 (t, J = 8.4 Hz, 
1H).  13CNMR (400 MHz, CDCl3) δ 14.3, 22.8, 29.1, 31.2, 31.9, 36.2, 70.5, 101.0, 
104.6(2), 112.9, 113.0, 120.1(2), 120.2, 127.8(2), 128.4, 128.9(2), 134.1(2), 136.7, 147.0, 
155.3, 160.4, 161.9. 
 
OHO
CN
F3C
 
2-(3-Hydroxy-phenoxy)-6-trifluoromethyl-benzonitrile (23a) 
General Method E.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:1) to afford 0.199 g (81%) of (23a) as 
a white solid:  Rf 0.08 (EtOAc/hexane, 1:4); mp 106–108 ºC.  1HNMR (400 MHz, 
(CD3)2CO) δ 6.77-6.71 (m, 2H), 6.80-6.82 (m, 1H), 7.28-7.34 (m, 2H), 7.66 (d, J = 7.6 
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Hz, 1H), 7.84-7.88 (m, 1H), 8.81 (broad s, 1, OH).  13CNMR (400 MHz, (CD3)2CO) δ 
101.6, 107.6, 111.1, 112.4, 113.2, 120.8(2), 121.7, 131.3, 135.3(2), 155.9, 159.5, 161.7. 
 
OHO
CN
F3C
 
2-(3-Hydroxy-5-methyl-phenoxy)-6-trifluoromethyl-benxonitrile (23b) 
 General Method E.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:1) to afford 0.588 g (57%) of (23b) as 
a light brown solid:  Rf 0.19 (EtOAc/hexane, 1:4). The oily residue was induced to 
crystallize by the addition of hexane; mp 73-75 ºC. 1HNMR (400 MHz, CDCl3) δ 2.29 (s, 
3H), 5.79 (broad s, 1, OH), 6.42-6.46 (m, 2H), 6.57 (d, J = 0.8 Hz, 1H), 7.10 (d, J = 8.8 
Hz, 1H), 7.43 (d, J = 7.6 Hz, 2H), 7.55-7.59 (m, 1H).  13CNMR (400 MHz, CDCl3) δ 
20.8, 101.2, 104.7(2), 111.9(2), 113.8, 120.6, 121.2, 135.2(2), 141.8, 155.7, 159.2, 161.8.  
MS (ESI) m/z 292.1 (M - 1).  Anal. Calcd. for C15H10F3NO2:  C, 61.44; H, 3.44; N, 4.78.  
Found:  C, 61.23; H, 3.77; N, 4.54.   
 
 
2-(3-Ethyl-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (23c) 
General Method E.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:3, 1:1) to afford 0.279 g (89%) of 
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(23c) as a yellow oil:  Rf 0.37 (EtOAc/hexane, 1:4).  1HNMR (400 MHz, CDCl3) δ 1.21 
(p, J = 13.0 Hz, 3H), 2.60(q, J = 12.0 Hz, 2H), 5.32 (s, 1H), 6.43 (t, J = 2.4 Hz, 1H), 6.51 
(broad s, 1, OH), 6.60 (t, J = 0.8 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 7.6 Hz, 
1H), 7.57 (q, J = 8.0 Hz, 1H).  13CNMR (400 MHz, CDCl3) δ 15.3, 28.9, 105.3(2), 112.2, 
112.7, 120.6, 120.3, 120.2(2), 134.2, 134.3, 148.5, 155.4, 157.4, 161.8.  MS (ESI) m/z 
342.1 (M + MeOH), 306.1 (M – O-).  Anal. Calcd. for C19H18F3NO2:  C, 62.54; H, 3.94; 
N, 4.56.  Found:  C, 62.44; H, 4.07; N, 4.35.   
 
 
2-(3-Propyl-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (23d) 
General Method E.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:3, 1:1) to afford 90.4 mg (41%) of 
(67d) as a yellow oil:  Rf 0.52 (EtOAc/hexane, 3:7).  1HNMR (400 MHz, CDCl3) δ  0.92 
(t, J = 7.2 Hz, 3H), 1.61 (q, J = 7.6 Hz, 2H), 2.52 (t, J = 7.6 Hz, 2H), 4.71 (broad s, 1, 
OH), 6.43 (s, 1H), 6.48 (s, 1H), 6.57 (s, 1H), 7.09 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 7.6 Hz, 
1H), 7.56 (t, J = 8.4 Hz, 1H).  13CNMR (400 MHz, CDCl3) δ 13.9, 24.3, 38.0, 100.2(2), 
105.4(2), 112.6, 113.5(2), 120.1, 134.5(2), 146.9, 155.1, 157.6, 162.1.  MS (ESI) m/z 
364.3 (M + 1), 382.4 (M + H2O), 386.2 (M + Na).  Anal. Calcd. for C20H20F3NO2•1/2  
H2O:  C, 64.51; H, 5.68; N, 3.76.  Found:  C, 64.62; H, 5.62; N, 3.64. 
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2-(3-Butyl-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (23e) 
General Method E.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:3, 1:1) to afford 86.7 mg (36%) of 
(23e) as a yellow solid:  Rf 0.62 (EtOAc/hexane, 1:4). The oily residue was induced to 
crystallize by the addition of hexane; mp 89-92 ºC.  1HNMR (400 MHz, CDCl3) δ 0.91 
(q, J = 7.6 Hz, 3H), 1.30-1.37 (m, 2H), 1.52-1.59 (m, 2H), 2.54 (t, J = 7.2 Hz, 2H), 6.14 
(broad s, 1, OH), 6.44 (t, J = 2.4 Hz, 1H), 6.47 (d, J = 2.0 Hz, 1H), 6.59 (dd, J = 1.6 Hz, 
1.2 Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.54-7.59 (m, 1H).  13CNMR (400 MHz, CDCl3) δ 
14.1, 22.4, 33.3, 35.7, 105.3(2), 112.6, 113.3, 120.1(2), 120.2(2), 134.2(2), 147.2, 155.3, 
157.5, 161.9.  MS (ESI) m/z 336.1 (M + 1), 353.3 (M + H2O), 358.1 (M + Na).  Anal. 
Calcd. for C18H16F3NO2:  C, 64.47; H, 4.81; N, 4.18.  Found:  C, 64.71; H, 4.85; N, 4.06.   
 
 
2-(3-Hydroxy-5-pentyl-phenoxy)-6-trifluoromethyl)-benzonitrile (23f) 
 General Method E.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:9, 1:7, 1:1) to afford 0.141 g (40%) of (23f) as a 
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white solid:  Rf  0.23 (EtOAc/hexane, 1:4).  The oily residue was induced to crystallize by 
the addition of hexane; mp 85-86 ºC. 1HNMR (400 MHz, CDCl3) δ 0.88 (q, J = 4.4 Hz, 
3H), 1.26-1.34 (m, 4H), 1.54-1.62 (m, 2H), 2.54 (t, J = 7.6, 2H), 5.51 (broad s, 1, OH), 
6.44 (t, J = 2.0 Hz, 2H), 6.49 (d, J = 2.0 Hz, 1H), 6.58 (s, 1H), 7.10 (d, J = 8.4 Hz, 1H), 
7.43 (d, J = 8.0 Hz, 1H), 7.54-7.58 (m, 1H).  13CNMR (400 MHz, CDCl3) δ 14.2, 22.7, 
30.9, 31.6, 35.9, 97.6, 105.2, 112.5, 112.9, 113.1, 115.6(2), 120.2(2), 134.1, 147.3, 155.4, 
157.1, 161.8.  MS (ESI) m/z 372.2 (M + Na).  Anal. Calcd. for C19H18F3NO2:  C, 65.32; 
H, 5.19; N, 4.01.  Found:  C, 65.50; H, 5.14; N, 4.01.   
O OH
CN
F3C
 
2-(3-Hexyl-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (23g) 
General Method E.  The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:3, 1:1) to afford 33.2 mg (8.4%) of 
(23g) as a yellow solid:  Rf 0.68 (EtOAc/hexane, 3:7). The oily residue was induced to 
crystallize by the addition of hexane; mp 88-91 ºC.  1HNMR (400 MHz, CDCl3) δ 0.86-
0.89 (m, 3H), 1.24-1.33(m, 6H), 1.54-1.60 (m, 2H), 2.54 (t, J = 8.0 Hz, 2H), 5.50 (broad 
s, 1, OH), 6.43 (t, J = 2.0 Hz, 1H), 6.49 (s, 1H), 6.58 (s, 1H), 7.10 (d, J = 8.4 Hz, 1H), 
7.43 (d, J = 7.6 Hz, 1H), 7.56 (t, J = 8.4 Hz, 1H).  13CNMR (400 MHz, CDCl3) δ 14.3, 
22.8, 29.1, 31.1, 31.8, 36.0, 105.3(2), 112.6(2), 112.8, 113.2, 120.1, 120.2, 134.1(2), 
147.3, 155.4, 157.2, 161.8.  MS (ESI) m/z 364.3 (M + 1), 382.4 (M + H2O), 386.2 (M + 
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Na).  Anal. Calcd. for C20H20F3NO2•1/2 H2O:  C, 64.51; H, 5.68; N, 3.76.  Found:  C, 
64.62; H, 5.62; N, 3.64.   
 
F3C
CN
O O
S CF3
O O
 
3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl 4,4,4-trifluoro-1-butane-sulphonate (14) 
 General Method F.  The residue was purified by preparative TLC (SiO2, gradient 
of hexane:CH2Cl2 3:7) to afford 0.129 g (40%) of 13 as a pale yellow oil:  Rf 0.38 
(CH2Cl2/hexane, 3:7).  The oily residue was induced to crystallize by the addition of 
pentane; mp 59-60 ºC.  1HNMR (400 MHz, CDCl3) δ 2.25-2.41 (m, 4H), 3.38 (t, J = 7.6 
Hz, 2H), 7.05-7.10 (m, 2H), 7.14-7.20 (m, 2H), 7.47-7.54 (m, 2H), 7.64 (t, J = 8.4 Hz, 
1H), 13CNMR (400 MHz, CDCl3) δ 17.1, 32.2 (q, JC-F  = 158), 49.6, 112.2, 114.5, 119.0, 
119.3, 120.4, 120.7, 121.3(2), 124.1, 128.3, 131.7, 134.5, 149.8, 155.7, 160.5.  MS (ESI) 
m/z 454.1 (M + 1). 
 
OF3C
CN
O
O
 
3-(2-Cyano-3-(trifluoromethyl)phenozy)phenyl acetate (24a) 
General Method G.  The residue was purified by flash chromatography (SiO2, 
gradient of hexane, CH2Cl2, EtOAc) to afford 46.5 mg (67%) of (24a) as a colorless oil:  
Rf 0.30 (EtOAc/hexane, 1:4).  1HNMR (400 MHz, CDCl3) δ 2.30 (s, 3H), 6.91 (t, J = 2.0 
Hz, 1H), 6.98-7.04 (m, 2H), 7.14 (d, J = 8.8 Hz, 1H), 7.43 (dd, J = 8.0 Hz, 8.8 Hz, 2H), 
7.60 (t, J = 7.6 Hz, 1H).  13CNMR (400 MHz, CDCl3) δ 21.3, 98.6, 112.3, 114.4, 
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117.7(2), 119.3, 120.3, 120.7(2), 124.1, 131.0, 134.3(2), 152.1, 155.1, 161.2, 169.2.  MS 
(ESI) m/z 322.3 (M + 1), 344.3 (M + Na), 339.3 (M + H2O).  Anal. Calcd. for 
C16H10F3NO3•1/4 C7H8:  C, 61.92; H, 3.51; N, 4.07.  Found:  C, 60.74; H, 3.66; N, 4.07.   
 
OF3C
CN
O
O
 
3-(2-Cyano-3-(trifluoromethyl)phenozy)phenyl propionate (24b) 
General Method G.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc/hexane 1:4) to afford 70.8 mg (61%) of (24b) as a white solid:  Rf 
0.25 (EtOAc/hexane, 1:4); mp 82-83 ºC.  1HNMR (300 MHz, CDCl3) δ 1.23 (t, J = 7.5 
Hz, 3H), 2.59 (q, J = 7.5 Hz, 2H), 6.91 (s, 1H), 6.91-7.04 (m, 2H), 7.13 (d, J = 8.4 Hz, 
1H), 7.41-7.49 (m, 2H), 7.60 (t, J = 8.1 Hz, 1H).  13CNMR (300 MHz, CDCl3) δ 9.16, 
27.9, 101.4, 112.4, 114.5, 117.6, 119.3, 120.2, 120.6, 124.2, 127.8, 131.0, 134.3, 152.3, 
155.0, 161.3, 172.8.  MS (ESI) m/z 454.1 (M + 1).  Anal. Calcd. for C17H12F3NO3•1/4 
H2O:  C, 60.09; H, 3.71; N, 4.12.  Found:  C, 60.20; H, 3.49; N, 4.16.   
 
OF3C
CN
O
O
 
3-(2-Cyano-3-(trifluoromethyl)phenoxy)phenyl butyrate (24c) 
General Method G.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc/hexane 1:4) to afford 0.128 g (69%) of (24c) as a pale yellow oil:  Rf 
0.54 (EtOAc/CH2Cl2, 1:4).  1HNMR (400 MHz, CDCl3) δ 1.03 (t, J = 7.6 Hz, 3H), 1.77 
(sextet, J = 7.6 Hz, 2H), 2.54 (t, J = 7.6 Hz, 2H), 6.90 (t, J = 2.4 Hz, 1H), 6.97-7.04 (m, 
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2H), 7.13 (d, J = 8.4 Hz, 1H), 7.42-7.48 (m, 2H), 7.57-7.62 (m, 1H).  13CNMR (400 
MHz, CDCl3) δ 13.8, 18.6, 36.4, 101.7, 112.4, 114.5, 117.6, 119.3, 120.2, 120.5, 120.6, 
131.0, 134.3(2), 152.2, 155.0, 161.3, 172.0.  MS (ESI) m/z 350.3 (M + 1), 372.3 (M + 
Na), 367.4 (M + H2O).  Anal. Calcd. for C20H20F3NO2•1/2 H2O:  C, 64.51; H, 5.68; N, 
3.76.  Found:  C, 64.62; H, 5.62; N, 3.64.   
 
OF3C
CN
O
O
 
3-(2-Cyano-3-(trifluoromethyl)phenoxy)phenyl pentanoate (24d) 
To a stirred solution of phenol (23a) (57 mg, 0.20 mmol) in Et3N (5 mL) valeryl 
chloride (29 µL, 0.24 mmol, 1.2 equiv) was added and refluxed for 2 h.  The solvent was 
removed under reduced pressure.  The residue was purified by column chromatography 
(SiO2, gradient of hexane, hexane/CH2Cl2 1:1, CH2Cl2, (CH3)2CO) to afford 57.1 mg 
(78%) of (24d) as a white solid:  Rf 0.50 (EtOAc/hexane, 1:4); mp 44-46 °C.  1HNMR 
(400 MHz, CDCl3) δ 0.96 (t, J = 7.2 Hz, 3H), 1.39-1.48 (m, 2H), 1.69-1.76 (m, 2H), 2.56 
(t, J = 7.2 Hz, 2H), 6.90 (t, J = 2.4 Hz, 1H), 6.97-7.03 (m, 2H), 7.13 (d, J = 8.8 Hz, 1H), 
7.41-7.48 (m, 2H), 7.57-7.61 (m, 1H).  13CNMR (400 MHz, CDCl3) δ 13.9, 22.4, 27.1, 
34.2, 101.3, 112.4, 114.5, 117.7, 119.4, 120.2, 120.6, 120.7, 123.7, 131.0, 134.3, 152.3, 
155.0, 161.3, 172.2.  MS (ESI) m/z 454.1 (M + 1).  Anal. Calcd. for C20H20F3NO2•1/2 
H2O:  C, 64.51; H, 5.68; N, 3.76.  Found:  C, 64.62; H, 5.62; N, 3.64.   
 
 
 100
OF3C
CN
O
O
 
3-(2-Cyano-3-(trifluoromethyl)phenoxy)phenyl hexanoate (24e) 
General Method G.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc:hexane 1:4) to afford 58.0 mg (74%) of (24e) as a colorless oil:  Rf 
0.56 (EtOAc/hexane, 1:4).  1HNMR (400 MHz, CDCl3) δ 0.91-0.94 (m, 3H), 1.36-1.40 
(m, 4H), 1.71-1.76 (m, 2H), 2.55 (t, J = 7.2 Hz, 2H), 6.90 (t, J = 2.4 Hz, 1H), 6.97-7.03 
(m, 2H), 7.13 (d, J = 8.4 Hz, 1H), 7.42-7.48 (m, 2H), 7.59 (t, J = 8.0 Hz, 1H).  13CNMR 
(400 MHz, CDCl3) δ 14.1, 22.5, 24.7, 31.4, 34.4, 112.3, 114.5, 117.6, 119.3, 120.2, 
120.6(2), 120.7, 123.7, 131.0, 134.3, 152.2, 155.0, 161.3, 172.1.  MS (ESI) m/z 378.3 (M 
+ 1), 400.4 (M + Na).  Anal. Calcd. for C20H18F3NO3:  C, 63.66; H, 4.81; N, 3.71.  
Found:  C, 63.84; H, 4.90; N, 3.65.  
  
F3C
CN
O O
Cl  
2-(3-(4-Chlorobenzyloxy)phenoxy)-6-(trifluoromethyl)benzonitrile (25a) 
General Method C.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc:hexane 1:4) to afford 40.6 mg (56%) of (25a) as a colorless oil:  Rf 
0.40 (EtOAc/hexane, 1:4).  The oily residue was induced to crystallize by the addition of 
hexane; mp 46-48 °C.  1HNMR (400 MHz, (CDCl3) δ 5.03 (s, 2H), 6.70 (st, J = 6.8 Hz, 
2H), 6.86 (td, J = 1.6 Hz, 2.0 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 7.31-7.37 (m, 5H), 7.45 
(d, J = 8.0 Hz, 1H), 7.55 (t, J = 8.0 Hz, 1H).  13CNMR (400 MHz, (CDCl3) δ 69.7, 107.5, 
112.5(2), 112.9, 120.3, 120.4, 120.5(2), 129.0(3), 129.1(2), 134.1(2), 135.0(2), 155.7, 
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160.4, 161.5.  MS (ESI) m/z 404.3 (M + 1), 426.3 (M + Na).  Anal. Calcd. for 
C21H13ClF3NO2:  C, 62.47; H, 3.25; N, 3.47.  Found:  C, 62.47; H, 3.25; N, 3.47. 
 
F3C
CN
O O
CF3  
2-(Trifluoromethyl)-6-(3-(4-(trifluoromethyl)benzyloxy)phenoxy)benzonitrile (25b) 
General Method C.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc:hexane 1:4) to afford 35.9 mg (71%) of (25b) as a colorless oil:  Rf 
0.37 (EtOAc/hexane, 1:4).  The oily residue was induced to crystallize by the addition of 
hexane; mp 65-66 ºC.  1HNMR (400 MHz, CDCl3) δ 5.13 (s, 2H), 6.72 (q, J = 1.6 Hz, 
2.8 Hz, 2H), 6.87 (td, J = 0.8 Hz, 2.0 Hz, 1H), 7.06 (d, J = 8.8 Hz, 1H), 7.33-7.37 (m, 
1H), 7.46 (d, J = 7.6 Hz, 1H), 7.55 (t, J = 10.8 Hz, 3H), 7.65 (d, J = 8.4 Hz, 2H).  
13CNMR (400 MHz, CDCl3) δ 69.6, 107.4(3), 112.5, 113.0, 120.3, 120.5(2), 125.8(2), 
129.9, 127.7(2), 131.2(2), 134.1(2), 140.6, 155.7, 160.2, 161.5.  MS (ESI) m/z 460.4 (M 
+ Na).  Anal. Calcd. for C22H13F6NO2·H2O:  C, 58.03; H, 3.32; N, 3.11.  Found:  C, 
57.71; H, 2.88; N, 2.88.  
 
F3C
CN
O O
OMe  
  2-(3-(4-Methoxybenzyloxy)phenoxy)-6-(trifluoromethyl)benzonitrile (25c) 
General Method C.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc:hexane 1:4) to afford 30.2 mg (64%) of (25c) as a white solid:  Rf 0.45 
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(EtOAc/hexane, 1:4); mp 103-105 ºC.  1HNMR (400 MHz, CDCl3) δ 3.82 (s, 3H), 4.98 
(s, 2H), 6.68 (dt, J = 1.6Hz, 2.0Hz, 2H), 6.87-6.93 (m, 3H), 7.06 (d, J = 8.4Hz, 1H), 7.33 
(t, J = 8.4Hz, 3H), 7.44 (d, J = 7.6Hz, 1H), 7.55 (t, J = 8.4Hz, 1H).  13CNMR (400 MHz, 
CDCl3) δ 55.5, 70.3, 107.5(3), 112.6, 114.3(3), 120.2, 120.3, 120.4, 128.5, 129.5(3), 
131.1, 134.1, 155.6, 159.9, 160.7, 161.6.  MS (ESI) m/z 417.5 (M + H2O), 422.4 (M + 
Na).  Anal. Calcd for C22H16F3NO3:  C, 66.16; H, 4.04; N, 3.51, Found:  C, 66.11; H, 
3.96; N, 3.51. 
 
F3C
CN
O O
Me  
2-(3-(4-Methylbenzyloxy)phenoxy)-6-(trifluoromethyl)benzonitrile (25d) 
General Method C.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc:hexane 1:4) to afford 38.5 mg (81%) of (25d) as a white solid:  Rf 
0.50 (EtOAc/hexane, 1:4); mp 91-93 ºC.  1HNMR (400 MHz, CDCl3) δ 2.37 (s, 3H), 5.01 
(s, 2H), 6.68-6.72 (m, 2H), 6.87-6.90 (m, 1H), 7.06 (d, J = 8.4 Hz, 1H), 7.20 (d, J = 8.0 
Hz, 2H), 7.29-7.35 (m, 3H), 7.44 (d, J = 7.6 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H).  13CNMR 
(400MHz, CDCl3) δ 21.4, 70.5, 107.5(3), 112.6, 120.2, 120.3(2), 120.4, 127.9(2), 
129.6(3), 133.5(2), 134.1, 138.3, 155.6, 160.7, 161.6.  MS (ESI) m/z 384.3 (M + 1), 406.3 
(M + Na), 401.3 (M + H2O).  Anal. Calcd. for C22H16F3NO2:  C, 68.93; H, 4.21; N, 3.65.  
Found:  C, 68.93; H, 4.21; N, 3.65. 
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F3C
CN
O O
Cl
Cl
 
2-(3-(3,4-Dichlorobenzyloxy)phenoxy)-6-(trifluoromethyl)benzonitrile (25e) 
General Method C.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc:hexane 1:4) to afford 35.4 mg (62%) of (25e) as a colorless oil:  Rf 
0.52 (EtOAc/hexane, 1:4).  The oily residue was induced to crystallize by the addition of 
hexane; mp 66-68 ºC.  1HNMR (400 MHz, CDCl3) δ 5.01 (s, 2H), 6.69-6.74 (m, 2H), 
6.84-6.87 (m, 1H), 7.07 (d, J = 8.8 Hz, 1H), 7.23-7.26 (m, 1H), 7.34 (t, J = 8.4 Hz, 1H), 
7.45-7.47 (m, 2H), 7.54 (td, J = 8.0 Hz, 0.4 Hz, 2H).  13CNMR (400 MHz, CDCl3) δ 69.0, 
107.4(3), 112.4, 113.1, 120.3, 120.5(2), 126.8, 129.5, 130.9, 132.4(2), 133.1, 136.8, 
134.1, 155.7, 160.1, 161.5, 131.2.   MS (ESI) m/z 437.5 (M - 1).  Anal. Calcd. for 
C21H12Cl2F3NO2:  C, 57.56; H, 2.76; N, 3.20.  Found:  C, 57.56; H, 2.76; N, 3.20. 
 
F3C
CN
O O
Br  
2-(3-(4-Bromobenzyloxy)phenoxy)-6-(trifluoromethyl)benzonitrile (25f) 
General Method C.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc:hexane 1:4) to afford 50.5 mg (78%) of (25f) as a white solid:  Rf 0.57 
(EtOAc/hexane, 1:4); mp  85-86 ºC.  1HNMR (400 MHz, CDCl3) δ 5.01 (s, 2H), 6.71 (t, J 
= 2.1 Hz, 2H), 6.84 (dd, J = 1.5 Hz, 2.1 Hz, 1H), 7.04 (d, J = 8.1 Hz, 1H), 7.25-7.35 (m, 
3H), 7.43-7.58 (m, 4H).  13CNMR (400 MHz, CDCl3) δ 69.7, 107.5(3), 112.5, 112.9, 
120.3, 120.4, 120.5, 122.3, 129.3(3), 131.1(2), 132.2, 134.5, 135.6, 155.6, 160.3, 161.5.  
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MS (ESI) m/z 430.6 (M - H2O), 413.6 (M - Cl).  Anal. Calcd. for C21H13BrF3NO2:  C, 
56.27; H, 2.92; N, 3.12.  Found:  C, 56.19; H, 2.88; N, 3.20. 
 
F3C
CN
O O
F  
2-(3-(4-Fluorobenzyloxy)phenoxy)-6-(trifluoromethyl)benzonitrile (25g) 
General Method C.  The residue was purified by preparative TLC (SiO2, 
gradient of EtOAc:hexane 1:4) to afford 36.9 mg (71%) of (25g) as a colorless oil:  Rf 
0.47 (EtOAc/hexane, 1:4).  The oily residue was induced to crystallize by the addition of 
hexane; mp 70-72 ºC.  1HNMR (400 MHz, CDCl3) δ 5.03 (s, 2H), 6.72 (d, J = 5.6 Hz, 
2H), 6.88 (d, J = 8.4 Hz, 1H), 7.07 (sd, J = 8.4 Hz, 3H), 7.27-7.42 (m, 3H), 7.46 (d, J = 
7.6 Hz, 1H), 7.56 (t, J = 8.4 Hz, 1H).  13CNMR (400 MHz, CDCl3) δ 69.9, 102.6, 
107.5(3), 112.5, 115.7(3), 120.4(2), 123.7, 129.6(2), 129.7, 132.3, 134.1(2), 155.7, 160.5, 
161.6, 164.1.  MS (ESI) m/z 388.4 (M + 1), 410.4 (M + Na), 405.4 (M + H2O).  Anal. 
Calcd. for C21H13F4NO2:  C, 65.12; H, 3.38; N, 3.62.  Found:  C, 65.03; H, 3.65; N, 3.39. 
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APPENDIX 
 
Synthesis of Diaryl Ether Analogues of BAY 59-3074 as Therapeutics of Marijuana 
Abuse 
 
X-ray Crystallographic Data, Positional Parameters, Thermal Displacement Parameters, 
Bond Distances, Bond Angles and Torsional Angles for 2-(3-hydroxyphenoxy)-6-
(trifluoromethyl)benzonitirile (23a). 
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Table 1:  Crystal data and structure refinement for 2-(3-hydroxyphenoxy)-6-
(trifluoromethyl)benzonitirile 
 
Empirical formula    C14H8F3NO2 
Formula weight    279.21 
Temperature     120(2) K 
Wavelength     0.71073 Å 
Crystal system    Monoclinic 
Space group     C2/c 
Unit cell dimensions    a = 33.373(7) Å α = 90º 
      b = 5.60004(12) Å β = 90.813(3)º 
      a = 13.231(3) Å γ = 90º 
Volume     2472.7(9)Å3 
Z      8 
Density (calculated)    1.500 Mg/m3 
Absorption coefficient   0.131 mm-1 
F(000)      1136 
Crystal size     0.50 x 0.50 x 0.01 mm3 
Theta range for data collection  2.44 to 28.23º 
Index ranges     -43<=h<=43, -7<=k<=7, -17<=l<=17 
Reflections collected    14417 
Independent reflections   8410 [R(int) = 0.0283] 
Completeness to theta = 28.33  100% 
Absorption correction    emperical 
Max. and min. transmission   0.9987 and 0.9374 
Refinement method    Full-matrix least-squares on F2 
Data/restraints/parameters   2879/0/213   
Goodness-of-fit-on F2    1.081 
Final R indices [I>2sigma(I)]   R1 = 0.0409, wR2 = 0.1075 
R indices (all data)    R1 = 0.0533, wR2 = 0.1266 
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Table 2:  Atomic coordinates (Å x 104) and equivalent isotropic displacement parameter (Åx 103)  
for 2-(3-hydroxyphenoxy)-6-(trifluoromethyl)benzonitirile (23a).  U(eq) is defined as 
one third of the trace of the orthogonalized Uij tensor. 
 
     x         y         z            U(eq) 
 
C(1)     2994(5) -1720(3) 7692(13)  29(3)  
C(2)      2761(5)  -1948(3)  0.6815(13)  30(4)  
H(2)      2576(6)  -3310(4)  0.6766(15)  32(5)  
C(3)      2784(5)  -295(3)  0.6036(12)  28(3)  
H(3)      2618(6) -430(4)  0.5422(15)  32(5)  
C(4)      3048(5)  1628(3)  0.6126(11)  25(3)  
O(5)      3064(4)  3219(2)  0.5346(9)  32(3)  
H(5)      3243(8)  4270(5)  0.5448(18) 51(7)  
C(6)      3285(5)  1887(3)  0.6995(12) 24(3)  
H(6)     3458(6)  3180(3)  0.7062(14) 25(4)  
C(7)      3251(5)  2110(3)  0.7754(11) 25(3)  
O(8)      3476(3)  650(2)  0.8644(8)  29(3)  
C(9)      3788(4)  -810(3)  0.8885(11) 24(3)  
C(10)     3990(4)  -239(3)  0.9792(11) 24(3)  
C(11)     3846(5)  1774(3)  10350(11)  25(3)  
N(12)     3726(4)  3421(3)  10763(10)  31(3)  
C(13)     4323(5)  -1609(3)  10100(12)  26(3)  
C(14)     4540(5)  -1001(3)  11072(13)  33(4)  
F(15)      4862(4)  -2358(3)  11232(9)  61(4)  
F(16)    4665(4)  1273(2)  11094(9)  51(3)  
F(17)      4305(3)  -1272(2)  11874(7)  42(3)  
C(18)     4450(5)  -3491(3)  9514(13)  31(4)  
H(18)     4680(6)  -4450(4)  9735(16)  38(5)  
C(19)     4249(5)  -4020(3)  8613(13)  31(4)  
H(19)     4340(6)  -5290(4)  8217(17)  43(6)  
C(20)     3921(5)  -2708(3)  8296(12)  28(3)  
H(20)     3784(6)  -3060(4)  7679(16)  32(5)  
H(1)     2972(6)  -2840(4)  8240(16)  35(5) 
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Table 3:  Bond lengths [Å] and angles [º] for 2-(3-hydroxyphenoxy)- 
    6-(trifluoromethyl)benzonitirile (23a) 
  
C(1)-C(7)   1.383(2)  
C(1)-C(2)   1.392(2)  
C(2)-C(3)   1.389(2)   
C(3)-C(4)    1.394(2)  
C(4)-O(5)   1.3645(19)  
C(4)-C(6)   1.394(2)    
C(6)-C(7)   1.381(2)   
C(7)-O(8)   1.4084(18) 
O(8)-C(9)   1.3588(19)  
C(9)-C(20)    1.393(2)   
C(9)-C(10)    1.406(2)   
C(10)-C(13)    1.406(2)  
C(10)-C(11)    1.435(2)   
C(11)-N(12)    1.147(2)  
C(13)-C(18)    1.379(2)  
C(13)-C(14)    1.505(2)  
C(14)-F(15)    1.331(2)   
C(14)-F(16)    1.340(2)   
C(14)-F(17)    1.337(2)   
C(18)-C(19)    1.392(2) 
C(19)-C(20)   1.379(2) 
C(7)-C(1)-C(2)  117.36(15)  
C(3)-C(2)-C(1)  121.41(15)   
C(2)-C(3)-C(4)  119.59(15)   
O(5)-C(4)-C(6)  121.86(14)   
O(5)-C(4)-C(3)  118.14(14)  
C(6)-C(4)-C(3)  120.00(14)   
C(7)-C(6)-C(4)  118.61(14)   
C(6)-C(7)-C(1)  123.02(14)  
C(6)-C(7)-O(8)  116.22(14)   
C(1)-C(7)-O(8)  120.62(14)   
C(9)-O(8)-C(7)  119.25(12)  
O(8)-C(9)-C(20)  125.22(14)  
O(8)-C(9)-C(10)  114.88(13)  
C(20)-C(9)-C(10)  119.87(14)  
C(13)-C(10)-C(9)  119.40(14)  
C(13)-C(10)-C(11)  123.32(14)  
C(9)-C(10)-C(11)  117.27(14)  
N(12)-C(11)-C(10)  177.37(16)  
C(18)-C(13)-C(10)  120.16(15)  
C(18)-C(13)-C(14)  120.35(15)  
C(10)-C(13)-C(14)  119.48(14)  
F(15)-C(14)-F(16)  106.81(16)  
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F(15)-C(14)-F(17)  106.86(15) 
F(16)-C(14)-F(17)  105.97(15)  
F(15)-C(14)-C(13)  112.58(14)  
F(16)-C(14)-C(13)  112.28(14) 
F(17)-C(14)-C(13)  111.91(14)  
C(13)-C(18)-C(19)  119.69(16)  
C(20)-C(19)-C(18)  121.25(16)   
C(19)-C(20)-C(9)  119.62(15)  
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Table 4:  Anisotropic displacement parameters (Å2 x 104) 2-(3-hydroxyphenoxy)- 
6-(trifluoromethyl)benzonitirile (23a).  The anisotropic displacement factor 
exponent takes the form: -2π2[h2 a*2 U11 + …+ 2 h k a* b* U12] 
 
 U11  U22  U33  U23  U13  U12 
 
C(1) 311(9)  266(8)  294(8)  38(6)  21(6)  13(6)  
C(2) 268(8)  257(8)  373(9)  -16(7)  -2(6)  -26(6)  
C(3)  260(8)  283(8)  288(8)  -43(6)  -56(6)  14(6)  
C(4)  276(8)  236(7)  225(7)  0(6)  -27(6)  31(6)  
O(5)  419(7)  309(6)  239(6)  42(5)  -85(5)  -42(5)  
C(6)  245(8)  234(7)  250(7)  -17(6)  -27(6)  -4(6)  
C(7)  263(8)  265(7)  221(7)  -16(6)  -34(5)  46(6)  
O(8)  366(6)  284(6)  223(5)  -23(4)  -75(4)  74(5)  
C(9)  269(8)  247(7)  199(7)  37(6)  0(5)  2(6)  
C(10)  270(8)  259(7)  189(7)  9(6)  18(5)  -4(6)  
C(11)  265(8)  295(8)  184(7)  23(6)  -17(5)  -3(6)  
N(12)  378(8)  312(7)  242(6)  -17(6)  -2(5)  27(6)  
C(13)  246(8)  321(8)  221(7)  11(6)  2(6)  10(6)  
C(14)  305(9)  416(9)  277(8)  -23(7)  -38(6)  65(7)  
F(15)  484(7)  880(10)  458(7)  -216(7) -230(5) 361(7)  
F(16)  552(8)  541(7)  425(7)  -13(6)  -160(5) -180(6)  
F(17)  487(7)  552(7)  215(5)  8(5)  -20(4)  30(5)  
C(18)  280(9)  354(9)  302(8)  -14(7)  -9(6)  61(7)  
C(19)  332(9)  320(9)  289(8)  -50(7)  33(6)  44(7)  
C(20)  327(9)  291(8)  207(7)  -18(6)  1(6)  -2(6)  
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Table 5:  Torsion angles [º] for 2-(3-hydroxyphenoxy)-6-(trifluoromethyl)benzonitirile (67) 
 
C(7)-C(1)-C(2)-C(3)       -0.5(2) 
C(1)-C(2)-C(3)-C(4)         0.5(2) 
C(2)-C(3)-C(4)-O(5)       179.95(14) 
C(2)-C(3)-C(4)-C(6)       -0.2(2) 
O(5)-C(4)-C(6)-C(7)       179.77(14) 
C(3)-C(4)-C(6)-C(7)       -0.1(2) 
C(4)-C(6)-C(7)-C(1)       0.1(2) 
C(4)-C(6)-C(7)-O(8)      -175.64(13) 
C(2)-C(1)-C(7)-C(6)       0.2(2) 
C(2)-C(1)-C(7)-O(8)       175.74(14) 
C(6)-C(7)-O(8)-C(9)       -112.10(16) 
C(1)-C(7)-O(8)-C(9)       72.1(2) 
C(7)-O(8)-C(9)-C(20)      2.7(2) 
C(7)-O(8)-C(9)-C(10)      -179.27(13) 
O(8)-C(9)-C(10)-C(13)      -178.64(13) 
C(20)-C(9)-C(10)-C(13)      -0.5(2) 
O(8)-C(9)-C(10)-C(11)      0.2(2) 
C(20)-C(9)-C(10)-C(11)      178.32(14) 
C(13)-C(10)-C(11)-N(12)      149(4) 
C(9)-C(10)-C(11)-N(12)      -29(4) 
C(9)-C(10)-C(13)-C(18)      0.1(2) 
C(11)-C(10)-C(13)-C(18)      -178.61(15) 
C(9)-C(10)-C(13)-C(14)      -179.98(14) 
C(11)-C(10)-C(13)-C(14)      1.3(2) 
C(18)-C(13)-C(14)-F(15)      3.7(2) 
C(10)-C(13)-C(14)-F(15)      -176.23(16) 
C(18)-C(13)-C(14)-F(16)      124.27(18) 
C(10)-C(13)-C(14)-F(16)      -55.6(2) 
C(18)-C(13)-C(14)-F(17)      -116.70(18) 
C(10)-C(13)-C(14)-F(17)      63.4(2) 
C(10)-C(13)-C(18)-C(19)      0.4(3) 
C(14)-C(13)-C(18)-C(19)      -179.53(16) 
C(13)-C(18)-C(19)-C(20)      -0.5(3) 
C(18)-C(19)-C(20)-C(9)      0.1(3) 
O(8)-C(9)-C(20)-C(19)      178.31(15) 
C(10)-C(9)-C(20)-C(19)      0.4(2) 
 
Symmetry transformations used to generate equivalent atoms 
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